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Abstract
Hsp104 is a hexameric, AAA+ disaggregase from yeast, which couples ATP hydrolysis to remodeling
diverse substrates ranging from amorphous aggregates to amyloid fibers. A mechanistic understanding
of Hsp104's substrate remodeling activities remains poorly defined. The hexamer undergoes large
conformational changes upon ATP hydrolysis, but the details of these changes and how they are coupled
to substrate remodeling are unresolved. The goals of this thesis were to elucidate low and high-resolution
structural information about the Hsp104 hexamer and to discover new details of the mechanism of
substrate remodeling.
We used the in solution structural techniques small angle x-ray scattering and synchrotron x-ray
footprinting, complemented by several biochemical assays, to elucidate novel roles for several Hsp104
domains, and to develop a comprehensive model for how the Hsp104 hexamer engages substrate and
unleashes its remodeling capabilities. We discovered that the N-terminal domain (NTD) is involved in
substrate binding, productive interactions with Hsp70, and an interface with nucleotide binding domain 1
(NBD1) and the middle domain (MD). We discovered a loop in NBD1 that may engage substrate in the
ADP bound state to prevent premature substrate release, identified the region of the MD (helix 2)
responsible and the mechanism of signal transmission between NBD1 and NBD2, and confirmed the
validity of a hexameric model of the NBD2 domain.
Hsp104 engages substrate in the ATP-bound state. We have found that in this state Hsp104 displays an
increase in rigidity, which we propose as a pre-payment of the entropic cost of substrate binding. Initial
substrate engagement in the NTD and NBD1, as well as Hsp70 interactions at the NTD:NBD1:MD
interface, serve to `prime the pump'. These interactions result in large conformational changes of the MD,
specifically in helix 2, which spans the entirety of the domain. These conformational changes increase
MD dynamics, partially releasing MD:NBD2 contacts, and allow signal transmission between NBD1 and
NBD2. As NBD2 responds to these signals, a positive feedback loop is created. Further nucleotide binding
in NBD2 stimulates ATP hydrolysis in NBD1, and substrate is remodeled by iterative binding events and
peristaltic motions of the Hsp104 hexamer channel.
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ABSTRACT
STRUCTURAL AND MECHANISTIC INSIGHTS INTO THE YEAST DISAGGREGASE HSP104
Elizabeth A Sweeny
Dr. James Shorter
Hsp104 is a hexameric, AAA+ disaggregase from yeast, which couples ATP hydrolysis to
remodeling diverse substrates ranging from amorphous aggregates to amyloid fibers. A
mechanistic understanding of Hsp104’s substrate remodeling activities remains poorly defined.
The hexamer undergoes large conformational changes upon ATP hydrolysis, but the details of
these changes and how they are coupled to substrate remodeling are unresolved. The goals of
this thesis were to elucidate low and high-resolution structural information about the Hsp104
hexamer and to discover new details of the mechanism of substrate remodeling.
We used the in solution structural techniques small angle x-ray scattering and
synchrotron x-ray footprinting, complemented by several biochemical assays, to elucidate novel
roles for several Hsp104 domains, and to develop a comprehensive model for how the Hsp104
hexamer engages substrate and unleashes its remodeling capabilities. We discovered that the Nterminal domain (NTD) is involved in substrate binding, productive interactions with Hsp70, and
an interface with nucleotide binding domain 1 (NBD1) and the middle domain (MD). We
discovered a loop in NBD1 that may engage substrate in the ADP bound state to prevent
premature substrate release, identified the region of the MD (helix 2) responsible and the
mechanism of signal transmission between NBD1 and NBD2, and confirmed the validity of a
hexameric model of the NBD2 domain.
Hsp104 engages substrate in the ATP-bound state. We have found that in this state
Hsp104 displays an increase in rigidity, which we propose as a pre-payment of the entropic cost
of substrate binding. Initial substrate engagement in the NTD and NBD1, as well as Hsp70
interactions at the NTD:NBD1:MD interface, serve to ‘prime the pump’. These interactions result
in large conformational changes of the MD, specifically in helix 2, which spans the entirety of the

v	
  
	
  

domain. These conformational changes increase MD dynamics, partially releasing MD:NBD2
contacts, and allow signal transmission between NBD1 and NBD2. As NBD2 responds to these
signals, a positive feedback loop is created. Further nucleotide binding in NBD2 stimulates ATP
hydrolysis in NBD1, and substrate is remodeled by iterative binding events and peristaltic motions
of the Hsp104 hexamer channel.
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Chapter 1: Background and significance

	
  
1.1

Protein folding
Proper cellular function and viability is dependent upon proteins being able to efficiently

fold into their functional, native states [1]. Not only does an inability to correctly fold prevent
proteins from performing their cellular functions [2-4], but unfolding and misfolding of proteins can
lead to protein aggregation, a state associated with numerous human diseases [1, 2, 4-7].
Anfinsen’s seminal work showed that a protein’s amino acid sequence contains all of the
information necessary for it to adopt its functional, three-dimensional shape[8] – but it turns out
that this is only part of an even more interesting story. More recent work has shown that proteins
are capable of accessing a number of different folds and oligomeric states, and emerging work
indicates that this is unlikely to be an evolutionary error [9, 10]. Not only do these different states
represent intermediates along multiple parallel folding pathways, but also the conformational
diversity of natively folded proteins [11, 12]. Small changes in energy can result in large
conformational changes [12] and these fluctuations allow proteins to sample a huge variety of
states, resulting in a dynamic ensemble of protein conformations at any given time [11, 12].
In addition to thermal fluctuations, which allow proteins to explore small changes in
conformation, some proteins can access a number of different conformational states based on
chemical and protein partners, and environmental conditions [13-18]. Indeed, a growing number
of proteins have been found to contain regions or domains that do not even fold into threedimensional structures under normal physiological conditions [15, 19]. These intrinsically
disordered proteins may adopt structure upon posttranslational modifications [13-15], ligand
binding [14-16] (often DNA or RNA), protein-protein interactions [15, 16], chaperone binding [17,
20], or environmental changes within the cell [18]. Many of these proteins are involved in crucial
cell regulatory pathways [15, 19], and control over their temporal and spatial activity along with
targeted degradation is critical for cell health [6]. The realization that there are ongoing protein
transitions between partially and fully folded states, monomeric and oligomeric states, and even
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the assembly and disassembly of large heterologous protein complexes, reveals that nature has
exploited the ability to control protein folding to regulate cellular functions.
The conformational state of proteins in the cell is, by necessity, tightly regulated.
Controlling the conformational state of the proteome in the crowded environment of the cell, 300400mg/mL [21], is not trivial. To minimize the presence of incorrectly folded proteins, the cell
contains chemical and molecular chaperones to help nascent and denatured polypeptides fold
[22, 23], protein-remodeling factors to rescue aggregated proteins [24, 25], and protein
degradation systems to clear the cell of proteins resistant to re-folding efforts [26, 27]. In addition
to these safeguards there are a number of factors that regulate controlled conformational shifts,
into stress granules [28, 29], functional amyloids and prions [20, 30-34], and other protein
complexes [9, 10] that may either activate, inactivate, or modify the activity of a given protein [9,
10, 20, 28-34]. When these transitions are improperly controlled, pathogenesis may occur [1].

1.2

Aggregation, amyloids and prions
There are two types of protein aggregates, disordered and ordered. Which type of

aggregation occurs is a function of protein sequence and environment, and a vast number of
proteins appear capable of accessing either aggregated state [35, 36]. Amorphous aggregates
are largely unstructured with little long-range order [35]. These aggregates can be induced in vitro
by exposure to heat and high protein concentrations and are soluble in chemical denaturants
such as SDS [35]. Amorphous aggregates have been found associated with human diseases
such as ALS [37, 38], multisystem proteinopathy [37], cancer [39], and cystic fibrosis [40].
Amyloid aggregates display stable long-range order comprised of characteristic cross-β
fibrils, in which the β-strands run perpendicular to the fiber axis [41-44]. The ends of the fibers act
as templates seeding the conformational change of natively folded versions of the protein into the
amyloid form [45]. Amyloid displays a number of physical characteristics such as a unique x-ray
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diffraction pattern resulting from the uniform, repeating fiber structure [41, 42], an ability to bind
certain dyes and change their spectroscopic qualities [46-48] (termed ‘amyloid binding dyes’ such
as Thioflavin T and congo red), a fibrillar morphology when viewed using electron microscopy
[48], and a resistance to solubilization by denaturants such as SDS [49, 50], heat [51] and even
proteases [52]. The term prion simply refers to infectious amyloid [7], meaning that the
conformational state can be passed to different individuals – such as mother to daughter
inheritance of yeast prions [53] – or between species – such as cow to human transmission in
bovine spongiform encephalopathy [54], or mad cow disease. Amyloids and prions are often
associated with human disease; cardiac amyloids, cardiomyopathy, cerebral amyloid angiopathy,
Alzheimer’s disease, Parkinson’s disease, type II diabetes, prion diseases and more [55, 56].
These diseases can stem from a number of factors including genetic mutation, environmental
stresses, or simply age [55, 56]. However, more recent work has revealed that amyloids and
prions are not always detrimental; in a growing number of cases they have been found to play
important roles in a number of organisms from bacteria to humans [20, 30-34]. Once again we
find that transitions from one conformational state to another are an important facet of natural
protein function, it is only when control over these transitions is lost that severe, sometime lethal,
complications develop [7].
The formation of amyloid occurs through a series of oligomeric species and eventual
nucleation of fibril growth [57] (Figure 1). A growing number of proteins have been found to be
capable of accessing the amyloid form and it has even been suggested that under the right
circumstances all proteins could adopt the amyloid conformation [36]. Generally, there is either a
region, or domain, which is largely unstructured [58], or there is an environmental shift that
causes some form of unfolding [59]. Sampling of conformational space by the unfolded regions
leads to the build-up of oligomeric species [57]. Initially, these oligomeric species are soluble, but
at some point there is a transition to insoluble oligomers with amyloid characteristics [57, 58].
There is evidence that in human disease some of these oligomers are responsible for cellular
toxicity [60-62] and therefore there has been an interest in characterizing the structure and other
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properties of these oligomers and understanding what controls the transition from one to another.
The ability to develop antibodies that recognize oligomeric, but not monomeric or fibrillar
conformations of a variety of amyloid forming proteins indicates that there are common structural
elements within the amyloidogenic oligomers [63]. When spontaneous amyloid formation is
tracked over time (i.e. in the absence of preformed amyloid), the result is a sigmoidal curve
(Figure 1); the interplay between different oligomeric species represents a lag phase, during
which time there is little to no amyloid characteristic [57]. During this slow, thermodynamically
unfavorable phase there is a diverse range of oligomeric structures sampled [57]. Details such as
temperature, buffer conditions and the presence of mutated proteins can have dramatic influence
over the nature of these oligomeric species [57]. The next phase of amyloid formation progresses
once nucleation occurs, i.e., amyloidogenic oligomers capable of seeding fiber formation have
evolved. During this polymerization, or exponential phase, the curve displays a rapid increase of
amyloid structure as the nucleated fibers grow from each end (Figure 1). These fiber ends act as
templates, converting soluble versions of the protein into the amyloid state [64]. The lag phase
can be shortened or even skipped altogether if amyloidogenic seed is added to the soluble
species [64]. Interestingly, there is evidence showing that under certain circumstances, crossseeding may even be possible [65-68], i.e., seeding amyloid formation of protein X by
amyloidogenic versions of protein Y. This behavior may have important implications for the
progression of a number of human diseases [65]. Eventually, fiber growth slows and the curve
plateaus; at this point an equilibrium has been reached between the amyloid and soluble species
[57]. Monomeric versions of the protein come off and onto the fiber ends, but as a whole the
large, fibrous structure remains highly stable [57].
Though the amyloid, or prion state of proteins has been largely associated with
devastating human diseases, it is not always an aberrant state [20, 30-34]. In yeast, prions act as
self-propagating, protein-based heritable elements; they display non-Mendelian segregation in
crosses [69, 70], can be cytoduced [71, 72], and reversibly cured [71, 73]. Yeast prions confer
diverse and often beneficial phenotypes to the cells that harbor them [74]. These changes can be
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+

due to partial loss of function, such as seen with [PSI ] [70, 75] and [URE3] [71], or the gain of a
+

+

+

novel function such as with [PIN ] [68], [ISP ] [76] and [MOD ] [77]. One of the best characterized
+

yeast prions, [PSI ], is comprised of the translation termination factor, Sup35 [78, 79]. The
depletion of soluble Sup35 upon prionogenesis results in the partial read-through of stop codons,
suppression of nonsense mutations [75] and access to novel gene products, some of which are
advantageous [53, 80].
+

Initially there were a limited number of yeast prions described, namely [PSI ] [20, 81, 82],
+

[URE3] [71, 83] and [RNQ ] [30, 84], and it was proposed that they may have been a by-product
of the yeast being cultivated in a laboratory environment [85]. However, more recently prions
have been found in a variety of wild-yeast strains, indicating that it is not a laboratory artifact [85].
Further, the discovery of at least 24 additional yeast proteins that appear to have a prion-forming
domain [86] indicates that use of the prion conformation may be a common mechanism in yeast.
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Prion-forming domains (PrDs) have been identified as necessary and sufficient to facilitate the
transition between the soluble and prion form [84, 87-89]. PrDs are largely unfolded and are often
rich in polar uncharged residues [90]. They are independent of functional domains, and can be
transferred to other proteins to induce the prion state [84, 88], while deletion of the PrD leads to
an inability to form prions [84, 88]. Interestingly, when an algorithm designed to identify novel
prion domains was applied to the human genome, a number of the identified proteins have been
found associated with devastating neurodegenerative diseases [91]. Many of the identified
domains are found in RNA-binding proteins, which are involved in the development and dynamics
of beneficial, aggregation-like structures such as stress granules [92]. This then returns us to the
theme of controlled protein aggregation playing a crucial role in normal cellular function. Tight
+

regulation over conformational transitions is essential, indeed, even in the case of [PSI ], a
potentially beneficial prion state, excessive amounts of aggregated Sup35 results in toxicity [93].
Understanding how yeast regulate their well-characterized prion states has broad
implications for understanding how higher eukaryotes may regulate the aggregation state of their
proteomes, as well as allow for the targeted design of novel therapeutics to use against aberrant
protein aggregation in human disease. Yeast employ both environmental signals and modulation
of chaperones expression levels to control the prion state of its proteins [77, 94, 95]. Certain
+

environmental stresses such as the presence of antifungals for [MOD ] [77], or ethanol for
+

[MOT3 ] [94], can induce the prion state of the Mod5 and Mot3 proteins respectively. The network
of chaperones that play a role in prionogenesis and curing is more complex, and is best
understood for the canonical prion protein, Sup35. Central to the regulation of prion state is the
AAA+ protein Hsp104, however, a number of other chaperones have been found to play
important roles in vivo, namely the Hsp70 system, which includes Hsp40 chaperones as well as
Hsp70 nucleotide exchange factors (NEFs) [95].
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1.3

Hsp104 function in yeast
Hsp104 is a hexameric, Hsp100 AAA+ (ATPases Associated with various cellular

Activities) [96, 97] disaggregase [98]. AAA+ proteins have been described as molecular machines
[99], coupling ATP hydrolysis to protein degradation [99, 100], remodeling and dismantling of
macromolecular complexes [97], translocation of proteins and nucleic acids [99, 101], as well as
resolubilization of aggregates [96, 102]. Hsp104 appears to be involved in all things aggregate in
the yeast cell; from amorphous aggregates formed after heat shock, to the regulation of prion
proteins, to control over the segregation of carbonylated, aggregated proteins in order to control
aging and cell death [103-105].
Hsp104 was originally discovered as a gene required for induced thermotolerance in
Saccharomyces cerevisiae [106]. When yeast cells were pre-incubated at 37°C for 30 minutes
prior to heat shock at 50°C for 20 minutes, the cells containing a wild-type version of the Hsp104
gene displayed a 100- to 1000-fold increase in survival compared to yeast lacking the Hsp104
gene[106]. After the initial discovery of its critical role in thermotolerance Hsp104 was found to
confer tolerance to ethanol, arsenite, and prolonged exposure to the cold as well [107]. Hsp104 is
a member of the ClpA/ClpB protein family [108]. Unlike Hsp70 chaperones, which can prevent
aggregation of unfolded polypeptides [22], or ClpA, which promotes proteolysis of proteins [109],
it was shown that Hsp104 protects cells from stress, including heat shock, through the
resolubilization and reactivation of insoluble protein aggregates [110, 111], generally once the
stress was removed.
It was subsequently discovered that Hsp104 plays a central role in the regulation of yeast
prions [112]. Hsp104 is necessary for the propagation of all known naturally occurring amyloid+

+

based yeast prions including [PSI ] [20, 81, 82], [URE3] [83] and [RNQ ] [30, 84], and
+

+

demonstrates concentration dependent effects on the yeast prions [PSI ] [82] and [MOD ] [77].
+

Prionogenesis of Sup35 and resulting mother-to-daughter transmission results in the [PSI ] [20,
81, 82] phenotype. Prionogenesis can either be promoted, and inheritance maintained, or it can
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be inhibited and even cured, i.e., the prion phenotype lost [82]. In vivo, Hsp104 deletion or over+

expression eliminates [PSI ] [82]. Pure protein biochemistry has revealed that low concentrations
of Hsp104 catalyze Sup35 prionogenesis by nucleating fiber assembly[20, 81], and by severing
fibers to increase the number of growing fiber ends[20, 81]. By contrast, at high concentrations
Hsp104 couples ATP hydrolysis to the disassembly of both Sup35 fibers and oligomers into noninfectious conformers[20, 81, 113]. In vivo, and in vitro, the concentration dependent activity is
tuned by the presence of Hsp70:Hsp40 pairs as well as NEFs [114].
A number of papers have dissected the role of various Hsp70:Hsp40 pairs as well as
NEFs in the prionogenesis of Sup35 [95]. Hsp70 chaperones are ATPases that bind and release
substrates that contain large regions of unfolded and non-natively folded polypeptide [22]. In the
ADP bound state Hsp70 has a high affinity for substrate, and in the ATP bound state the affinity is
much lower [22]. This difference in affinity results in rounds of substrate binding and release,
which prevents interactions with other unfolded proteins that could lead to aggregation, as well as
giving the substrates the chance to re-fold into the native state upon their release [22]. However,
the basal rate of ATP hydrolysis for Hsp70 is very low, and therefore they require the activity of
Hsp40 proteins, which contains ATPase stimulating J-domains [22]. In addition to Hsp40, there
are a number of NEFs, which stimulate the exchange of ADP for ATP [22]. There are two Hsp70
+

subfamilies that have been shown to affect [PSI ], Ssa, whose four members are found
throughout the cytoplasm [115] and Ssb, whose two members are mostly associated with the
+

ribosome [116]. While Ssb is always a [PSI ] antagonist [117-119], Ssa has been shown to either
+

promote [117, 120-123] or antagonize [118, 121, 124] [PSI ] based on protein partners and
environmental factors (Figure 2).
Ssa1 mainly collaborates with the Hsp40 proteins Ydj1 and Sis1 [125] while Ssb1
requires a heterodimer of Zuo1, an Hsp40, and Ssz1, an atypical Hsp70 [126]. Fes1 and Sse1
are NEFs that are able to facilitate nucleotide exchange for both Ssa1 and Ssb1 [127-130]. The
Ssb1:Zuo1:Ssz1 complex, generally associated with the ribosome, is a potent antagonist of
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Sup35 prionogenesis [114]. Although unable to rapidly disassemble preformed Sup35 prions
[114], a number of Hsp70:Hsp40 pairs appear to bind both Sup35 oligomers and fibers,
disassembling soluble oligomers [114] and blocking nucleation and seeding events [114]. These
+

activities allow for overexpression of Hsp70:Hsp40 to cure certain [PSI ] phenotypes [118, 124].
The Hsp40 proteins Sis1 and Ydj1 preferentially interact with the Sup35 oligomers and fibers
rather than the monomers and promote Ssa1 and Ssb1 binding [114]. The NEF Sse1 was found
to directly stimulate prionogenesis of the prion domain of Sup35 [123], while Fes1 had no effect
[114]. Though Fes1 had no direct effect on Sup35 prionogenesis, it was found to diminish the
inhibitory effects of Hsp70:Hsp40 [114]. Fundamental to the balance of this complex chaperone
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network is the protein Hsp104 [95]. Based on its expression levels and collaboration with the
previously described Hsp70 system, it is the main determinant of prion state (Figure 2).
The prion stimulating activity at low Hsp104 concentrations was found to be capable of
overriding the inhibitory activities of Hsp70:Sis1 pairs, but not Hsp70:Ydj1 pairs [114].
Additionally, ex vivo Sup35 fibers contain a large amount of Ssa1/2; ~one Ssa1 for every two
Sup35 molecules, as well as smaller amounts of Ssb1, Ydj1 and Sis1 [131]. Incorporation of
Hsp70 and Hsp40 into the Sup35 fibers makes them better substrates for remodeling by high
concentrations of Hsp104 [114]. Though in vivo there appears to be a delicately balanced
interplay between Hsp104, Hsp70, Hsp40 and NEFs, in vitro experiments have demonstrated that
Hsp104 displays robust activity promoting, inhibiting or remodeling Sup35 fibers on its own in a
concentration dependent manner [20, 81, 114]. Indeed, it has even been shown that Hsp104 has
the ability to remodel amyloid forms of a number of human proteins involved in disease [132], a
feat that its bacterial homologue, ClpB, is unable to achieve [132].
More recently Hsp104’s role in aging was revealed [104, 105]. In the budding yeast
Saccharomyces cerevisiae, oxidatively damaged, aggregated proteins are retained in the mother
cell in an Hsp104-dependent manner [104, 105]. Disruption of this asymmetric inheritance of
aggregates results in accelerated aging of the progeny [104]. Interestingly, in the fission yeast
Schizosaccharomyces pombe aging does not occur under normal conditions, however, after the
yeast is subjected to stress some of the cells begin to age and become more likely to die [133].
This increased chance of death is due to the asymmetric inheritance of large, Hsp104-associated
aggregates formed in response to stress [133]. By forming one large aggregate which segregates
asymmetrically to only one cell, the yeast are able to sacrifice one cell in return for the health of
the others.
Overall, the activity of Hsp104 appears to be focused on the control of the aggregation
state of a number of proteins as well as the spatial localization of aggregates [103, 134]. The
questions then become almost endless: How does Hsp104 carry out these activities? Does it
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employ the same mechanism for all of its diverse substrates? Can it sense differences in stability
between a disordered and amyloid aggregate? When does its function shift from remodeling, to
sequestration of aggregates? Is remodeling coupled to sequestration? To understand and begin
to answer these questions we need to examine details about the structure and possible
mechanisms of the Hsp104 hexamer.

1.4

Hsp104 mechanism and structure

1.4.1

Overview
A mechanistic understanding of Hsp104’s substrate remodeling activities remains poorly

defined [135]. An Hsp104 monomer is 908 residues and 102kD; the fully assembled hexamer is a
large, hollow, barrel shaped molecule [102, 136] with 12 sites capable of ATP binding and
hydrolysis. The hexamer undergoes large conformational changes upon ATP hydrolysis [137,
138], but the details of these changes as well as how they are coupled to substrate remodeling is
unclear. There are no high-resolution structures, and most mutagenesis analyses have relied on
random mutagenesis, or focused on a few highly conserved residues such as those found in the
nucleotide binding pockets [138]. Hsp104 is comprised of five domains, the N-terminal domain
(NTD), two nucleotide-binding domains (NBD1 and NBD2), a coiled-coil middle domain (MD)
inserted within NBD1, and a unique C-terminal extension [138]. The hexameric structure of
Hsp104 remains unresolved. In fact, two radically distinct models have been advanced [135].
Both are based on cryo-EM reconstructions with rigid body fit domains from the crystal structure
of the Thermus thermophilus homolog, tClpB [102]. Unfortunately, tClpB was resolved as a spiral
of 3 ClpB monomers with distinct conformations, rather than the functional, hexameric state [102].
Using assumptions based on other AAA+ proteins and poorly documented cryo-EM
reconstructions of chemically fixed tClpB, an initial hexameric structure with an external
placement of the coiled-coil was proposed [102]. However, this structure was incompatible with
the dimensions of Hsp104 hexamers observed by another cryo-EM study [136]. This led to a

11	
  
	
  

second model with the coiled-coil domain intercalated between the two nucleotide-binding
domains [136]. However, this new model did not preserve the typical AAA+ nucleotide binding
sites, and the debate over the hexameric structure continues [135]. The stability of the hexamer is
affected by the presence of nucleotide [139] and salt concentration [140]. Nucleotide binding
stabilizes the hexamer, while high salt concentrations favor the monomer and smaller oligomers
such as dimers and trimers. The domains appear to cooperate in a highly tuned manner in order
to remodel diverse substrates and substrate structures [132]. Each domain plays specific roles,
and allosterically communicates with adjacent domains and subunits [138]. However, the details
of intra- and inter-protomer communication, and precisely what role(s) the individual domains play
in substrate remodeling are not fully resolved.

1.4.2

The N-terminal Domain (NTD)
Crystal structures of the N-terminal domains of the bacterial Hsp100 proteins ClpA [141],

ClpB [102, 142], and ClpC [143] have been solved. The NTDs are highly structurally conserved;
they are very stable globular domains [141-144] made up of two imperfect repeats of four helical
bundles [141-143] and are connected to the adjacent nucleotide-binding domain by a highly
mobile linker [102, 145-147]. In the bacterial disaggregase ClpB, Hsp104’s orthologue, the NTD
appears to be involved in substrate binding [102, 142, 148-151], casein-stimulated ATPase
activity [148], and its mobility via the NTD-NBD1 linker is necessary for efficient translocation and
disaggregation of substrate [152, 153].
In contrast to the bacterial Hsp100 proteins, the function of the Hsp104 N-terminal
domain has been poorly explored. In vivo, deletion or specific point mutations (e.g. T160M) within
the N-terminal domain has little effect on thermotolerance or prion propagation [154]. Therefore,
Hsp104 can still dissolve heat-denatured aggregates and fragment prions. Yet, over-expression
+

of these mutants fails to cure [PSI ] [154]. This suggests that Hsp104’s ability to eliminate amyloid
conformers is selectively perturbed and that there may be a fundamental difference in how
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amorphous and amyloid substrates are remodeled. Indeed, a recent paper found that
cooperativity of the subunits was dispensable for reactivation of amorphous aggregates, while
global cooperativity was needed for remodeling of amyloid substrates [132]. This indicates that
the NTD may be essential for global cooperativity. In addition to this possibility, the NTD of
Hsp104 may participate in substrate binding and interactions with adapter proteins such as
Hsp70, although the role(s) of the Hsp104 NTD remains unknown.

1.4.3

Nucleotide Binding Domains (NBD1 and NBD2)
Hsp104 contains two canonical AAA+ domains, designated NBD1 and NBD2. Each NBD

contains highly conserved AAA+ motifs but belong to different AAA+ clades (subgroups) [155].
These clades are defined by the insertion of specific secondary structure elements within the core
AAA+ fold, and have specific functional consequences [155, 156]. Since the NBDs belong to
different clades, (clade 3 for NBD1 and clade 5 for NBD2) it has been proposed that the protein
arose from a gene fusion event rather than a gene duplication event [155]. Each domain is able to
bind and hydrolyze ATP, but they have very different catalytic properties [140]. By fitting the
steady-state kinetics of ATP hydrolysis to two independent allosteric sites, and following up with
mutational analyses, the general properties of the two NBDs were determined [140]. NBD1
contains a low affinity, high turnover site and NBD2 a high affinity, low turnover site [140]. Both
domains display positive cooperativity, and a high degree of allosteric communication between
the two, e.g., hydrolysis in NBD1 depends upon the nucleotide state of NBD2 [140].
The nucleotide binding domains of AAA+ proteins are highly structurally conserved,
consisting of a large, α/β subdomain and a small α-helical subdomain [156]. Features that define
these domains include regions involved in ATP binding and hydrolysis, namely the Walker A and
Walker B motifs, the arginine finger, sensor-1 and sensor-2 residues (Figure 3), as well as pore
loops that couple conformational changes of the AAA+ protein due to ATP hydrolysis to substrate
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remodeling [155]. In addition to the conserved AAA+ motifs, NBD2 was discovered to contain a
nuclear localization signal (NLS) [157].
The P-loop, or Walker A motif, is common in a number of ATPases and GTPases and
has the consensus sequence GXXXXGKT/S [158, 159]. The Walker A residues, particularly the
highly conserved lysine, are involved in interactions with the phosphates of the bound nucleotide
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[155] (Figure 3). Indeed, the lysine residues K218 in NBD1 and K620 in NBD2 of Hsp104 are
essential for nucleotide binding [160]. By separately mutating conserved Walker A residues in
either NBD1 (G217V or K218T) or NBD2 (G619V or K620T), it was revealed that NBD1
contributes the majority of the ATPase activity, while NBD2 is responsible for nucleotide-induced
hexamerization [160]. The Walker B motif has the consensus sequence hhhhDE [158], where h
represents a hydrophobic residue. The aspartate residue can coordinate Mg

2+

while the

glutamate is thought to activate the attacking water in order to facilitate ATP hydrolysis [156]. In
Hsp104, as well as many other Hsp100 proteins, mutation of the Walker B glutamate residues,
E285 in NBD1 and E687 in NBD2, does not disrupt nucleotide binding but does inhibit hydrolysis
(Figure 3). An interesting consequence of this is that since most AAA+ proteins, including
Hsp104, engage substrate in the ATP-bound state, double Walker B mutants (E285Q/A:E687Q/A
in Hsp104) can be used as substrate ‘traps’ [161]. This allows for a number of interesting
biochemical investigations.
The sensor-1 and sensor-2 motifs can participate in various activities including ATP
binding, hydrolysis, discriminating between ADP and ATP, and the propagation of conformational
changes upon hydrolysis [162]. The sensor-1 residue is found in a structurally conserved region
called the secondary region of homology (SRH) [163]. It is a polar residue, generally Asn or Thr,
which interacts with regions of the Walker B motif as well as the γ-phosphate of the bound ATP
molecule [156]. Mutation of these conserved residues in Hsp104, T317 in NBD1 and N728 in
NBD2, reduces the ATPase rate but does not affect nucleotide binding [140]. Although both
sensor-1 mutants display a loss-of-function phenotype in vivo, the NBD2 mutant N728A is active
in vitro in the presence of ATP and the absence of Hsp70:Hsp40, a condition in which the wildtype protein is not active [113]. Why exactly this would be is unclear and underscores how hard it
is to get a comprehensive picture of mechanism in a protein as large and complex as Hsp104.
The sensor-2 motif, GAR, is located in the small α-helical subdomain and the conserved Arg
interacts with the γ-phosphate of the bound ATP [163]. In Hsp104 NBD1 does not appear to have
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a sensor-2 motif [102]. In NBD2 mutation of the conserved Arg, R826, results in an equal
decrease in binding to both ADP and ATP, as well as a decrease in ATP hydrolysis in NBD1
[164]. At the far end of the SRH from sensor-1 is the arginine finger, which completes the ATPbinding pocket (Figure 3). AAA+ proteins are oligomeric and the nucleotide-binding pocket is
located at the subunit:subunit interface [155]. An essential component of the catalytic site is the
arginine finger, which reaches from one protomer into the active site of its neighbor, contacting
the nucleotide [165]. In Hsp104 the arginine fingers are R334 in NBD1 and R765 in NBD2 and
mutation of these conserved arginines results in a loss of ATPase activity. A schematic of a
typical AAA+ catalytic site is shown in Figure 3 with AAA+ features based on the pdb 3glf [166].
The pore loops, or substrate binding loops, have the general consensus sequence YVG,
and couple the large conformational changes that take place during ATP hydrolysis to the
remodeling of substrate [167-169]. These conserved loops are on the interior of the axial channel,
which runs the length of the hexamer N-to C-terminally [102, 136] and facilitate partial and/or full
translocation of substrate through the channel [109, 167, 168, 170]. In Hsp104 the NBD1
substrate-binding loop is 256-KYKG-259, and in NBD2 the more typical 661-GYVG-664; the
highly conserved tyrosine residues, Y257 and Y662 are the most essential for substrate binding
[167]. In vivo, Y257A displays a reduction in survival after heat shock of only ~10-fold, while
Y662A fared only slightly better than having no Hsp104 at all [167]. This implies that Y662 is the
more crucial residue, and that there may be additional substrate binding motifs in NBD1 and the
NTD. Fluorescence studies showed that nucleotide binding in NBD2 determines the position of
residue 662 [167], which supports the idea that conformational changes due to ATP hydrolysis
are transmitted through the pore loop to the substrate.

1.4.4

Middle domain (MD)
Hsp104 and its bacterial homologue ClpB contain a ~85Å long coiled-coil middle domain

(MD) inserted into the small α-helical subdomain of NBD1 [102]. In the two hexameric models
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proposed for Hsp104 and ClpB, the position of the middle domain is the most highly contested. In
one model, the domain is intercalated between NBD1 and NBD2 [136, 137] while in the other it
projects out into solution [171]. The MD consists of four helices that make up an anti-parallel,
broken coiled-coil [102]. Helix 1 and half of helix two are designated motif 1, with the second half
of helix 2 along with helices 3 and 4 designated motif 2 (Figure 4). Helix 3 appears to undergo
conformational changes in response to nucleotide, possibly transitioning between loop and helix
[102, 172].
The MD is essential for disaggregation activity [145, 173] and is the site of interaction
with Hsp70 [172-175]. The MD has been shown to interact with NBD1 in an auto-inhibitory
fashion, repressing activity of the hexamer [172, 175-177]. Hsp70 binds directly to the MD,
specifically in the region of helix 2 in motif 2 [174, 175, 178]. This interaction appears to relieve
the autoinhibitory interactions between the MD and NBD1 [174, 175, 178]. Thus, it appears that
the MD is a highly dynamic domain involved in regulation of the hexamer activity. Indeed, point
mutations in the MD can lead to inactive variants with stabilized MD-NBD1 interactions [176], or
hyperactive variants with enhanced unfolding power [176, 179]. Recent findings have begun to
uncover the role and characteristics of the MD, however, many of the details of the placement,
dynamics and the mechanism of MD-mediated regulation remain unresolved.

1.4.5

C-terminal Domain (CTD)
Hsp104 contains a unique C-terminal extension of ~50 residues. The region is enriched

in acidic residues, and the last four residues are a conserved DDLD motif that allows binding to
the chaperone Cpr7 [180], although the importance of this interaction remains unknown as
deletion of the motif does not affect thermotolerance [180]. The CTD was initially thought to be a
main site of substrate interaction [181], and CTD binding to lysine rich polypeptides stimulates
ATPase activity in NBD1 via the MD [181]. However, subsequent work supported a model in
which substrates are translocated N- to C-terminally [111, 161], which leaves poly-Lys binding at
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the CTD of mysterious function. More recently, the CTD was shown to be essential for
hexamerization [180, 182], and though the sequence indicates that it is highly disordered, this
role implies that may not necessarily be the case.

1.5

Research aims
Hsp104 is a large, dynamic, multi-domain hexamer that couples large conformational

changes due to ATP hydrolysis to applying mechanical force to myriad substrates [138]. A better
understanding of the structure and mechanism of Hsp104 will not only allow insight into its natural
function, but open the door for directed evolution and protein design to tailor Hsp104 to
specifically remodel disease associated aggregates, as well as other therapeutic and research
purposes.
The goals of this thesis were to elucidate low and high-resolution details about the
structure and substrate remodeling mechanism of Hsp104. First, I set out to determine the role of
the Hsp104 NTD and to visualize large conformational changes of the hexamer using
SAXS/WAXS in order to make and test predictions about the structure and mechanism of
Hsp104. Specifically, we first aimed to understand why deletion of the NTD (ΔN-Hsp104) resulted
in an inability to remodel amyloid substrates and to use our findings to understand mechanistic
details of the wild-type hexamer. Secondly, we used an in solution technique, x-ray footprinting
(XF), that directly probes the solvation state of the Hsp104 hexamer in the presence of different
nucleotides. The changes in solvation allowed us to make predictions about what these
conformational changes mean for the individual domains, the Hsp104 hexamer as a whole, and
the mechanism of substrate remodeling. Using a variety of biochemical techniques, we tested
these predictions and were able to elucidate novel insights into substrate binding and processing,
interaction with Hsp70, movements of the coiled-coil middle domain, and the subunit:subunit
interface.
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Chapter 2:

The role of the N-terminal domain (NTD) of Hsp104

	
  
2.1

NTD introduction
The bacterial Hsp100 proteins ClpA [183] and ClpB [148] have internal start sites which

allow for the production of truncated protein products missing the N-terminal domain (NTD).
These natural Hsp100 truncations as well as other N-terminal truncations have been examined in
the literature for ClpA and ClpB as well as other AAA+ proteins. The activity of these truncated
products varies depending upon the identity and structure of the substrate [141, 144, 145, 148,
149, 183], and the location of the truncation [141, 144, 145, 148, 183, 184]. The crystal structures
of the NTDs of the bacterial Hsp100 proteins ClpA [141], ClpB [102, 142], and ClpC [143] have
been solved. The NTDs are structurally conserved; they are very stable globular domains [141144] made up of two imperfect repeats of four helical bundles [141-143] and are connected to the
NBD1 domain by a highly mobile linker [102, 145-147]. Strikingly, though the structure of the
repeats differs in content, other AAA+ proteins such as mammalian p97 and NSF also have
NTDs that contain two subdomains [185] connected to the NBD1 domain via mobile linkers [186,
187], and the NTDs may play similar roles in activity [187-190].
For the bacterial Hsp100s, though the effects vary with the details of substrate and the
location of the N terminal truncation, the NTD as well as the linker between the NTD and NBD1
domains have been shown to play a role in a number of functions. These include regulation of
binding and hydrolysis of ATP in the nucleotide binding domain(s) [144, 148, 183, 187], substrate
interaction [102, 141, 142, 144, 148-151], binding to adaptor proteins [141, 143, 188-192] and
controlling access to the central channel [136, 146, 184].
The NTD is not directly involved in ATP hydrolysis, however, the deletion of the NTD has
been shown to affect the behavior of the ATP-binding domains [144, 148, 183, 187]. These
effects are not always the same and vary depending on whether the NTD to NBD1 linker is also
removed [144, 148, 183, 187]. In ClpA, NTD deletion has been shown to decrease the ATPase
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rate [144, 183], in ClpB, eliminate the stimulation of ATPase rate by substrate [148], and in p97
the linker, along with the NTD-NBD1 interface has been shown to control the number of ATP
molecules that the NBD1 domain can bind at a given time [187]. Mutations in these regions in p97
have been linked with inclusion body myopathy with early-onset Paget disease and
frontotemporal dementia (IBMPFD), a devastating autosomal dominant degenerative disease
[187].
The region of the NTD that binds substrate is a highly-conserved hydrophobic patch that
is exposed to solvent and lies between the two subdomain repeats [102, 141, 142, 144, 150].
Even p97, with its divergent NTD structure retains a hydrophobic pocket between its NTD
subdomains [188], though it binds an adaptor protein p47 rather than substrate [188]. Near the
hydrophobic patch are two acidic residues that have been implicated in substrate binding in ClpB
[150], specifically involved in processing large aggregates [150]. In ClpA the corresponding
residues are arginine and alanine, and it has been proposed that the sequence variation is
related to differences in substrate specificity [150].
Several AAA+ proteins require binding of adaptor proteins for proper hexamer formation
[143, 193], determining substrate specificity [141, 191], or for stimulation of activity [24, 141, 188190, 193-195]. Many of these adaptor proteins interact with the NTD [141, 143, 188-190]. In the
case of ClpC and its adaptor protein MecA and ClpA with its adaptor protein ClpS, the exact site
of interaction is conserved [141, 143]. In fact, the only examples of non-NTD sites of adaptor
protein interaction occur in the MD, a unique coiled-coil domain inserted within the first
nucleotide-binding domain in Hsp104 and ClpB [172-175, 196]. ClpC has a truncated version of a
coiled-coil middle domain [143]. Interestingly, the ClpC-MecA interaction occurs at both the NTD
and the MD [143].
Despite the plethora of data on bacterial Hsp100 NTDs, there is very little published
information on the NTD of the AAA+ yeast protein Hsp104, which, like ClpA [109] and ClpB [170],
is able to unfold and translocate substrates through its central channel [167]. Curiously, Hsp104
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does not have a corresponding internal start site, which could imply that the NTD of Hsp104 plays
a more crucial role in activity than NTDs of its bacterial homologues. This may be due to
+

Hsp104’s unique in vivo role in regulating various yeast prions including [PSI ] [20, 81, 82],
+

[URE3] [83] and [RNQ ] [30, 84]. In yeast, prions act as nonchromosomal heritable elements [30,
53, 80], which can confer selective advantages in times of stress [53, 80]. From in vivo yeast
studies, it has been shown that the N terminal domain of Hsp104 is not necessary for
thermotolerance or yeast prion propagation, but is essential for curing of the yeast prion
phenotype [PSI+] caused by Sup35 prions [154, 197]. This finding led to the hypothesis that the
Hsp104 NTD may play an essential role in the unique ability of Hsp104 to remodel amyloid
substrates, specifically, the ability to eliminate the infectious cross-beta structure, as opposed to
simple fragmentation without altering the cross-beta structure [198].
In this chapter I present data from structural and biochemical techniques to understand
the role of the Hsp104 NTD. We wanted to understand how the NTD contributes to Hsp104
function, and therefore illuminate new details of how Hsp104 remodels amyloid aggregates into
non-infectious forms. This work elucidates, for the first time, the essential role of the NTD in
cooperativity of the hexamer. Recent work in our lab revealed that the ability of the Hsp104
hexamer to remodel amyloid substrates depends upon a high degree of plasticity and the ability
to operate in a fully cooperative manner [132]. The following work details how deletion of the NTD
results in a stable Hsp104 hexamer with a diminished ability to undergo productive
conformational changes, specifically in the channel running the length of the hexamer. This
profound alteration in conformational changes leads to defects in hexamer cooperativity. These
defects in cooperativity then lead to deregulation of the ATPase cycle and various functional
defects. These findings establish that the Hsp104 NTD is crucial for robust Hsp104 activity,
necessary for the global cooperativity needed for amyloid remodeling, and explain why an internal
start site is not found in the Hsp104 gene. The NTDs of Hsp100 proteins are often removed for
ease of in vitro biochemical characterization. Our work implicates that this practice, at least for

22	
  
	
  

Hsp104, could lead to drastic changes in how the hexameric assemblies function, even if activity
remains.

2.2 Results
2.2.1

The NTD is required for inhibition of Sup35 amyloid formation in vitro
Yeast studies have shown that the NTD of Hsp104 is required for curing the yeast prion
+

+

phenotype [PSI ] through Hsp104 overexpression [154, 197]. The [PSI ] prion phenotype is
caused by the translation termination factor, Sup35, forming infectious amyloid conformations [78,
79]. Pure protein biochemistry using Sup35 has been shown to recapitulate the in vivo
concentration dependent activity of Hsp104 on prions [20, 81]. At low concentrations Hsp104
promotes amyloidogenesis by nucleating fiber formation as well as severing the fibers to increase
the number of growing ends [20, 81]. Conversely, at high concentrations, Hsp104 is able to
completely remodel the Sup35 amyloid fibers into non-infectious, soluble conformations [20, 81,
113, 114]. We decided to test whether deletion of the NTD resulted in defects in prion remodeling
in vitro.
Using Sup35 as our model substrate we monitored amyloid formation over time using an
amyloid binding dye, Thioflavin T (ThT), which increases in fluorescence when bound to amyloid
[47]. We also used negative stain electron microscopy (EM) to visualize the reaction products. By
adding either WT Hsp104 or a NTD truncation mutant (ΔN Hsp104), we could monitor how
deletion of the NTD affected the ability of Hsp104 to alter the conformational state of Sup35. We
began by testing the effect on Sup35 amyloid assembly at a concentration shown to be inhibitory,
a ratio of Sup35 monomer to Hsp104 hexamer of 15:1 [20]. We found that while the WT Hsp104
inhibited amyloid assembly as expected, ΔN Hsp104 enhanced fibrilization (Figure 1A). Since this
behavior resembled what occurs at low concentrations of WT Hsp104 [20, 81], we next tested
whether we would see inhibition of Sup35 fibrilization at higher ΔN Hsp104 concentrations. We
found that even up to a ratio of Sup35 monomer to ΔN Hsp104 hexamer of 3:1, Sup35 amyloid
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formation was enhanced by the ΔN Hsp104 variant (Figure 1B). Our ThT findings were confirmed
by negative stain EM. Low concentrations of both WT and ΔN Hsp104 (75:1 Sup35 monomer to
Hsp104 hexamer) promoted Sup35 amyloid fiber formation (Figure 1C). At high concentrations,
WT Hsp104 inhibits the formation of amyloid fibers (instead shifting the species toward
amorphous, ThT negative Sup35 aggregates), while ΔN Hsp104 continues to promote amyloid
fiber formation (Figure 1C).

2.2.2

Deletion of the NTD results in an increase in ATPase rate
Since we found the NTD to be essential, in vitro, for the inhibition of Sup35 amyloid

formation, we sought to determine what role the domain plays in hexamer function. Since ATP
hydrolysis is required for the successful remodeling of Sup35 amyloid fibers [20], we wanted to
test whether the ATPase rate of the ΔN Hsp104 variant was altered. The NTD is not directly
involved in ATP binding or hydrolysis, however, the NTD of homologous proteins have been
shown to play a role in regulating these events in neighboring domains [144, 148, 183, 187].
Surprisingly, the ATPase rate of ΔN Hsp104 was approximately 2-fold higher than the WT
Hsp104 (Figure 2A). This shows that while ΔN Hsp104 is unable to inhibit Sup35 amyloid
formation, it is not a functionally inactive hexamer. Further, this finding supports a role for the
NTD of Hsp104 in regulating the ATPase rate of the hexamer.
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2.2.3

Deletion of the NTD does not affect maximal inherent disaggregase activity, but

does increase sensitivity to ATP:ATPγS ratios
We next wanted to assess whether the truncated hexamer was effective at in vitro
amorphous aggregate remodeling, for which we used a luciferase reactivation assay, which
assesses disaggregation and reactivation of chemically denatured firefly luciferase [132]. By
supplementing reaction conditions with different ratios of ATP:ATPγS, Hsp104 is able to
disaggregate amorphous aggregates in the absence of the Hsp70 system [113]. Since ΔN
Hsp104 displayed an elevated ATPase activity we were curious to find out if the ideal ATP:ATPγS
ratio would differ from that of WT Hsp104. Our findings were surprising. Although both the WT
and ΔN Hsp104 hexamers reached a peak activity at a ratio of 1:1 ATP:ATPγS, the ΔN hexamer
was much more sensitive to changes in nucleotide ratios than the WT protein (Figure 2B). At a
ratio of 2:1 ATP:ATPγS, WT Hsp104 shows statistically insignificant differences in activity to the
WT protein at a ratio of 1:1 ATP:ATPγS. However, ΔN Hsp104, which shows no statistically
significant difference in activity compared to WT Hsp104 at a ratio of 1:1 ATP:ATPγS is only
about 50% (p < 0.02) as active as WT Hsp104 at a ratio of 2:1 (Figure 2B). This finding indicated
that while the ΔN Hsp104 retained activity under specific conditions, it had lacked the robustness
needed for activity at a broad range of ATP:ATPγS ratios.

2.2.4

Deletion of the NTD leads to changes in conformation of the Hsp104 hexamer
To determine the basis for the specific defects of ΔN Hsp104, and to use these findings

to enhance our understanding of the WT protein, we wanted to visualize changes in the shape of
the hexamer through the ATPase cycle for WT Hsp104 as well as ΔN Hsp104. For this we used
the in solution structural technique Small (and Wide) Angle X-ray Scattering (SAXS/WAXS). To
simulate the steps of the ATP hydrolysis cycle, in solution scattering experiments were carried out
on the full-length protein (WT) and ΔN Hsp104 in six different states: in the presence of AMPPNP, ATPγS, ATP, ADP-AlFx (an ATP hydrolysis transition state mimic), ADP, and no nucleotide.
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Monodispersity of both the WT and ∆N Hsp104 constructs was assessed using size
exclusion chromatography coupled to multi-angle light scattering (SEC-MALS). A single peak
elutes as expected for a hexameric assembly, and using the inline multi-angle scattering and
refractive interferometer, an exact molecular weight can be calculated which corresponds to the
theoretical weight of the hexameric particle (Figure 3A). The molecular weights obtained by SECMALS compare favorably to the theoretical molecular weights of the two hexamers (Figure 3A).
Both WT and ΔN Hsp104 particles also have linear Guinier regions (Figure 3B) in all nucleotide
states, indicating that there are no interparticle interactions such as aggregation [199]. We
measured scattering for each sample at multiple concentrations as well as different beamlines
(SSRL 4-2 and NSLS X9) and obtained similar results in each case (Table 1). None of the
samples showed signs of aggregation or any other concentration-dependent effects.
Examples of raw scattering profiles (I(Q) vs. Q, where Q=4π(sinθ)/λ) and a
representative GNOM [200] fit to the experimental data are shown for WT and ∆N Hsp104 in the
presence of ADP in Figure 4A. Distinctive features in the low Q region that are present in all of
the WT Hsp104 samples but not the ∆N Hsp104 samples are highlighted by the inset in Figure
4A. A summary of Rg and Dmax values is reported in Table 2, as calculated by the program GNOM
[200] which uses an indirect Fourier transform to convert reciprocal space information into real
space information. The values reflect the average (including standard error) of measurements at
varying concentrations and two beamlines. The reproducibility of the measurement is evidence
that the samples are well behaved and ideally suited for SAXS analysis. The change in Rg is
displayed as a bar graph in Figure 4B, with the nucleotide states ordered to represent a round of
ATP hydrolysis (AMP-PNP, a non-hydrolysable ATP analog, ATPγS, a slowly hydrolysable ATP
analog, ATP, which in our WT Hsp104 may be partially hydrolyzed, ADP-AlFx, an ATP hydrolysis
transition state mimic, ADP, and the no nucleotide state). These values represent the average
dimensions of the Hsp104 hexamer in the presence of the various nucleotides.
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The Rg and Dmax values indicate that in the absence of nucleotide the Hsp104 hexamer is
expanded relative to the hexamer in the presence of nucleotide (Figure 4B, Tables 1 and 2). A
decrease in hexamer dimensions occurs upon addition of nucleotide, the magnitude of which is
reproducibly dependent on the identity of the nucleotide (Figure 4B, Tables 1 and 2). Compared
to the WT Hsp104 hexamer, the magnitude of the decrease in the ∆N Hsp104 hexamer
dimensions is markedly more pronounced in the transition from the no nucleotide to nucleotide
bound state (Figure 4B, Table 2). This decrease indicates that in the absence of nucleotide the
∆N Hsp104 hexamer is more expanded than the full-length protein. For both proteins AMP-PNP
and ATPγS, non-hydrolysable and slowly hydrolysable ATP analogs respectively, have the
largest Rg values (Figure 4B, Tables 1 and 2). The ADP-AlFx states have the smallest Rg (Figure
4B, Tables 1 and 2). These data suggest that both WT and ∆N Hsp104 hexamers contract upon
nucleotide binding, reaching their smallest dimension in the presence of the transition state mimic
ADP-AlFx, and then expanding slightly in the ADP state (Figure 4B, Table 2). This finding
indicates that the hexamer contracts and expands in concert with ATP hydrolysis (Figure 4B,
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Tables 1 and 2). The Dmax values for the WT and ∆N Hsp104 hexamers are comparable to each
other for all of the nucleotide states, suggesting that the maximum dimension maybe a
longitudinal rather than a simple N- to C- terminal vector (Tables 1 and 2).
Additional information about the conformational changes of the hexamers can be
garnered from the real-space pairwise density distribution function, or P(r), which is also obtained
by the indirect Fourier transform of the raw scattering data by the program GNOM [200].
Representative P(r) curves for the WT (Figure 5A) and the ∆N (Figure 5B) hexamers are shown
for all nucleotide states. For ease of comparison the curves have been normalized to the area
under the curve and overlaid. The area surrounding the peak of the P(r) curves has been
enlarged as an inlay to show the differences between nucleotide states (Figure 5). As with the Rg
values there are clear changes in shape dependent upon the identity of the nucleotide. Not
surprisingly, the most striking difference is seen in the ∆N Hsp104 hexamer in the absence of
nucleotide, where the particle is enlarged compared to the nucleotide bound states (Figure 5B).
The P(r) curves demonstrate that the addition of nucleotide, and the identity of the
nucleotide, induces specific conformational changes in both the WT and ∆N Hsp104 hexamers.
However, how the Hsp104 hexamer responds to nucleotide, both in terms of the magnitude and
the specific effect of a given nucleotide, differs in the absence of the NTD. To visualize these
changes, and how they differ between the WT and ∆N Hsp104 hexamers we used an ab initio
modeling program GASBOR [201] to acquire volume reconstructions of the average shape of the
particles in each nucleotide state (Figures 6 and 7). For each state, GASBOR was run on the raw
scattering data 10 times. The outputs of each GASBOR run were then averaged together to give
a filtered and unfiltered density using the program DAMAVER [202]. An overlay of every
GASBOR output for each state is shown in Figure 6. The WT shape reconstructions were
oriented using the ∆N hexamers (Figure 7B) which when overlaid showed where density for the
missing domain would fit. The large conformational changes are clearly visible, in particular the
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placement of a projection of external density. This projection is evident in the P(r) as well, as a
population of large vectors evidenced by the P(r) tails that start around 175 Å, that represent a
small amount of overall density (Figure 5). Both the WT and ∆N Hsp104 hexamers appear to
have dynamic projections that travel from more N- to C- terminal positions through the simulated
ATPase cycle (Figure 7A and C). The relatively large Rg and broadened P(r) curve of the ∆N
Hsp104 hexamer in the absence of nucleotide is explained by the expanded cavity as seen by the
view down the center of the reconstruction (Figure 7C).
Being able to visualize the average shape of the hexamers in each nucleotide state
allows us to define how the particle changes through the nucleotide cycle. However, we know that
the remodeling activity of Hsp104 is dependent upon translocation of substrate either fully or
partially, through the central pore of the hexamer [167]. To understand how the central channel
changes through the ATPase cycle we reconstructed the volume of the channel from the
averaged GASBOR reconstructions (Figure 8). The average diameter of the channel
reconstructions, N- C- terminally, are shown as bar graphs in Figure 8A (for WT) and Figure 8B
(for ∆N). Each bar represents one angstrom, and the number of bars represents the length of the
channel that is closed for 360 degrees. The motions of the WT Hsp104 channel are highly
reminiscent of a peristaltic wave (Figure 8A). In a peristaltic wave there is a relaxation at the site
of substrate entrance, followed by a wave of constriction that travels in the direction the substrate
is being pumped . Experiments have shown that substrate enters N-terminally and can be fully
translocated out the C-terminal end of the channel [111]. In the ATPγS/ATP states, when the
hexamer is capable of binding substrate, the extreme N-terminal side is open (Figure 8A). After
the opening there is a region of constriction, still N-terminal (Figure 8A, arrow). As we step
through the simulated ATPase cycle, the channel first constricts fully, correlating with the smallest
Rg, in the ADP-AlFx transition state mimic, and then the point of constriction moves toward the Cterminus in the ADP state (Figure 8A). This peristaltic pumping motion, similar to how an
esophagus moves food boluses, explains how the Hsp104 hexamer is able to transduce energy
from ATP hydrolysis to conformational change and substrate remodeling using physical force.
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The role of the NTD in facilitating the peristaltic pump motion is both simple and
significant. It becomes clear looking at the channel reconstructions why, in the absence of
nucleotide, the ∆N Hsp104 hexamer is expanded (Figure 8B). In the absence of nucleotide, in the
WT Hsp104 channel, the N-terminal region is contracted and the entire assembly elongated and
open on the C-terminal end (Figure 8A). In the absence of the NTD the channel is unable to
contract, rather, the entire hexamer is smaller in the N- to C-terminal direction, and the channel
appears to have a uniformly large diameter throughout (Figure 8B). As the ∆N Hsp104 channel
progresses through the ATPase cycle, it is clear that the missing domain is essential for the
proper movements of the channel. This defect is most obvious in the transition state mimic ADPAlFx, which is constricted in the center but open on both sides (Figure 8B). While there still
appears to be an area of contraction that shifts N to C-terminally, it is clear that the peristaltic
motion is greatly perturbed in the ∆N hexamer (Figure 8B). Specifically, it appears that substrate
could more readily diffuse out of the N-terminal opening of the channel of the ∆N Hsp104
hexamer.
Our SAXS/WAXS findings indicate that deletion of the NTD results in expansion of the
ends of the central cavity (similar to a cryo-EM study of the ∆N Hsp104 hexamer [136]), as well
as abnormal changes of the central channel during the ATPase cycle (Figure 8). Since ΔN
Hsp104 is unable to undergo nucleotide-dependent changes in the central channel similar to WT
Hsp104, we hypothesized that these structural defects may result in a diminished ability to
translocate substrate through the Hsp104 hexameric channel.
2.2.5

Deletion of the HAP NTD results in an increase in Km, and a decrease in Vmax for

casein degradation
To determine whether ΔN Hsp104 had a translocation defect as implied by the
SAXS/WAXS data we determined a Km and Vmax of casein degradation (Figure 9A) for both the
full length and ΔN versions of HAP. HAP is an Hsp104 mutant (739-GSK-741 to 739-IGF-741)
that is able to interact with the chambered peptidase ClpP [111]. HAP and ΔN HAP retain ATPase
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activity that is indistinguishable from WT and ΔN Hsp104 respectively (Figure 2A). In the
presence of ClpP, substrates that are translocated through the Hsp104 variant HAP are degraded
rather than released [111]. Therefore, using FITC-casein as a substrate we are able to assess
translocation efficiency by monitoring increases in FITC fluorescence as a proxy for casein
degradation, as FITC-casein is translocated and degraded, FITC is released. The ΔN HAP variant
displayed an increased Km as well as a reduced Vmax (Figure 9A), revealing that it is a less
effective translocase as predicted from the SAXS/WAXS data.

2.2.6

Deletion of the NTD results in a defect in substrate unfolding
Next we wanted to ascertain whether ΔN Hsp104 also displayed a defect in substrate

unfolding. To assess unfoldase activity we used a RepA1-70-GFP unfolding assay [113], where
decreases in fluorescence are used to measure GFP unfolding. To track unfolding of our RepA170-GFP

substrate in the absence of subsequent refolding, we added GroEL

TRAP

[203], which

captures the unfolded RepA1-70-GFP and prevents it from refolding [203]. By using permissive
ratios of ATP:ATPγS we see that WT Hsp104 robustly unfolds the RepA1-70-GFP substrate
(Figure 9B and C). WT unfolding activity is strongest with a 1:1 ATP:ATPγS, but remains strong at
a 2:1 ratio (Figure 9B and C). In contrast, ΔN Hsp104 has partial RepA1-70-GFP unfoldase activity
at a 1:1 ATP:ATPγS, but is unable to unfold RepA1-70-GFP at a ratio of 2:1 ATP:ATPγS (Figure 9B
and C). This result indicates 1) that ΔN Hsp104 retains some, but not WT levels of unfoldase
activity, and 2) Hsp104 unfoldase activity is more sensitive to changes in ATP:ATPγS than
luciferase reactivation is (Figures 2B and 9B), indicating that productive disaggregation of
disordered luciferase aggregates makes different demands on the Hsp104 hexamer than full
substrate unfolding.
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2.2.7

The NTD of Hsp104 is essential for hexamer cooperativity
Recent work in our lab revealed that WT Hsp104 employs different degrees of

intersubunit coordination to remodel disordered aggregates versus amyloid aggregates [132].
Dissolution of disordered aggregates does not require global cooperativity (i.e., all subunits
binding substrate and hydrolyzing ATP in concert, or in a specific order), rather, non-cooperative
probabilistic substrate binding and ATP hydrolysis are sufficient (i.e., subunits binding substrate
and hydrolyzing ATP independently of each other) [132]. In contrast, dissolution of amyloid
aggregates requires global cooperativity of the hexamer subunits [132], and Hsp104 hexamers
that contained subunits with defects in cooperativity were unable to remodel amyloid substrates
[132]. Since ΔN Hsp104 is also unable to remodel amyloid substrates (Figure 1), displays defects
in ATPase regulation (Figure 2A), and is unable to undergo conformational changes reminiscent
of the WT Hsp104 hexamer (Figure 8), we hypothesized that the NTD may be necessary for
hexamer cooperativity.
To test this hypothesis, we used a mutant subunit doping strategy [132]. Hsp104 subunits
with specific defects (such as ATP binding or hydrolysis) are mixed with WT, or in our case, ΔN
subunits, to generate ensembles of heterohexamers. Incorporation of the mutant subunits to
create heterohexamer ensembles occurs according to a binomial distribution dependent upon the
ratio of WT:mutant [132] (Figure 10A). Since the heterohexamers assemble based on a binomial
distribution, and the Hsp104 mutants retain no activity on their own, theoretical activities for each
ratio of WT:mutant can be determined based on the fraction of each type of heterohexamer
present at each WT:mutant ratio, and how many active subunits are required for activity [132]
(Figure 10B). If cooperativity is dispensable for activity, then only one WT subunit per hexamer is
required, and a linear decrease in activity would be expected [132] (Figure 10B, orange line). If
global cooperativity is required, a steep decline in activity would be expected [132] (Figure 8B,
blue line), and if some form of sub-global cooperativity (i.e., more than one but less than six
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subunits binding substrate or hydrolyzing ATP cooperatively) were required, an intermediate
curve [132] (Figure 10B) would be expected. For our doping experiments we used the full-length
WT Hsp104 with mutants in the full-length background, as well as ΔN Hsp104 and mutants in the
ΔN Hsp104 background. The mutants we used were double Walker B (DWB, E285Q:E287Q)
which can bind, but not hydrolyze ATP, double pore loop (DPL, Y257A:Y662A) which is defective
in substrate binding [204], and the combination mutant, DWBDPL (E285Q:E287Q:Y257A:Y662A)
which cannot hydrolyze ATP or bind substrate. In doping experiments with DWB or DWBDPL, we
saw that ΔN Hsp104 behaved similarly to WT Hsp104 (Figure 10C and D). Luciferase reactivation
was very sensitive to DWB subunits, ~5-6 WT/ΔN subunits per hexamer are necessary for activity
(Figure 10C). By contrast, luciferase reactivation was much less sensitive to DWBDPL subunits,
and luciferase reactivation required only one functional subunit per hexamer (Figure 10D). These
findings indicate that defects in ATP hydrolysis are tolerated as long as the subunits defective in
hydrolysis do not bind substrate (the DWB variant has been described as a substrate ‘trap’ [161],
since substrate binds in the ATP state, and therefore substrate would be prevented from
translocating through the Hsp104 channel if some subunits were bound to ATP as well as
substrate). It also tells us that even though ΔN Hsp104 displays deregulated ATPase activity, it
behaves similarly to WT Hsp104 in response to the addition of ATPase-dead subunits. We
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obtained very different results with the DPL subunits, which are defective in substrate binding.
When we doped these subunits into the ΔN and full length WT Hsp104, we found that in the
absence of the NTD results in a dramatic enhancement of activity in the presence of the DPL
subunits (Figure 10E). This finding implies that in the absence of the NTD the Hsp104 subunits
are behaving in a negatively cooperative manner in respect to substrate binding. This finding
suggests that the NTD is essential for productive cooperativity of the Hsp104 hexamer, a finding
strongly supported by the defects in the conformational changes seen in the SAXS/WAXS data
(Figures 5, 7 and 8).

2.2.8

Intersubunit cooperativity mediated by the NTD is essential for potentiation of the

Hsp104 hexamer
Through random mutagenesis our lab has discovered Hsp104 mutants that are
potentiated and capable of remodeling diverse substrates involved in human proteinopathies that
are intractable to WT Hsp104 [179]. These mutations, in motif 2 of the middle domain (MD),
appear to relieve autoinhibition of the hexamer and display increased activity in a variety of in
vitro assays as well as suppressing toxicity of human disease associated proteins in both S.
cerevisiae and C. elegans [179]. We decided to test whether these potentiating mutations (A503S
and A503V) could overcome the defects in cooperativity of ΔN Hsp104. We found that in the ΔN
Hsp104 background the potentiating mutations were unable to suppress toxicity of TDP-43, FUS
(TDP-43 and FUS are connected to amyotrophic lateral sclerosis [205]), or α-synuclein (αsynuclein is connected to Parkinson’s disease [206]) (Meredith Jackrel, Figure 11A-C). Since we
know that global cooperativity is required for remodeling amyloid substrates [132], and that TDP43, FUS and α-synuclein form highly recalcitrant aggregates, this finding provides further
evidence that the NTD is essential for global cooperativity of the Hsp104 hexamer. Further, it
would appear that cooperativity of the hexamer trumps potentiation conveyed through these
missense mutations.
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2.3

Conclusions
We have found that the Hsp104 NTD is necessary for nucleotide-dependent

conformational changes that allow productive hexamer cooperativity. While cooperativity is
dispensable for disordered aggregate dissolution, it is necessary for robust and adaptable
hexamer function. This deficiency in hexamer cooperativity due to defects in conformational
changes results in a deregulated ATPase rate, diminished unfoldase and translocase activity, and
an inability to remodel exceptionally stable substrates such as amyloid, even in the presence of
potentiating mutations. This role in global cooperativity is unexpected and novel for an Hsp100
NTD, and if unique to Hsp104 could explain why amyloid substrate remodeling has only been
observed with Hsp104 and not its bacterial homologue ClpB.
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Chapter 3:
3.1

X-ray footprinting (XF) as a probe of Hsp104 solvation

XF introduction
The functional Hsp104 hexamer is large and highly dynamic with an expansive, solvent

filled channel running the length of the macromolecule [136, 171]. In response to nucleotide
binding and hydrolysis, the hexamer undergoes substantial changes in conformation [137, 176].
These changes in conformation are coupled to remodeling diverse substrates, from thermallydenatured aggregates [110] to amyloid conformers [20, 81, 113]. To understand the details of
these conformational changes and how they may be driving substrate remodeling, a clearer
picture of Hsp104 structure and dynamics is necessary. Hsp104 is too large for NMR analysis
and has been refractory to crystallization attempts, therefore high-resolution structural information
is lacking. The bacterial homologue tClpB has been crystallized, but as a monomer [102]. Two
hexameric models have been proposed, based on rigid body fits of homology-modeled Hsp104
into cryo-EM maps [136, 171]. However, the models disagree dramatically, and dynamics of the
hexamer have been poorly defined. Elucidating details about the hexameric Hsp104 and how it
changes in response to nucleotide is important to understanding how these changes mediate
substrate remodeling.
We aimed to use a hybrid approach to learn structural and mechanistic details of the
Hsp104 hexamer. By combining homology modeling of the individual domains, volume
information from small angle x-ray scattering, crosslinking and mutational analysis, secondary
structure information from hydrogen-deuterium exchange and solvation information from x-ray
footprinting, we aimed to develop structural and mechanistic models that can explain
observations from the literature as well as allow us to predict novel mechanistic details that can
be tested biochemically. Central to our approach is the information garnered from synchrotron xray footprinting experiments. X-ray footprinting is a technique that probes the solvent accessibility
of the side-chains of a protein [207-209]. This allows for the identification of regions that are
involved in conformational changes and protein-protein interactions [207-209].

55	
  
	
  

Synchrotron x-ray footprinting uses millisecond bursts of high-flux x-rays to produce large
amounts of hydroxyl radicals through the radiolysis of water [207, 210]. Hydroxyl radicals are
ideal footprinting reagents because of their similarity to water molecules, making them excellent
probes for solvation, and their high and well-characterized reactivity with 19 of the 20 of the
amino acid side chains [207, 211, 212] (excluding glycine). Once hydroxyl radical-mediated
footprinting has been carried out on a protein sample, the oxidized products can be detected
using quantitative liquid-chromatography-coupled mass spectrometry [211, 213] (Figure 1).
Identification of the reaction products can be achieved using methods based on hydrogendeuterium (HD) exchange analyses [214, 215]. The abundance of unmodified and oxidatively
modified versions of a peptide is used to calculate the fraction unmodified [207, 208, 216] (Figure
1). For any given peptide, there can be a number of different modified versions, since each
residue can undergo different modifications, and different side chains on the same peptide may
be modified [207, 212, 213]. All singly modified peptides are quantified and added to the sum of
modified peptide [207, 208, 213]. Peptides that have more than one modification are not included
in the sum, as they may represent solvation-independent oxidation which can occur after the
initial, solvent-dependent modifications [211, 217]. The fraction unmodified for each identified
peptide is determined for a number of millisecond time points (Figure 1). The rate of hydroxyl
radical-mediated oxidative modification of each peptide is determined by fitting the dose response
curve to a first order decay [208, 213, 216] (Figure 1). At the longest timepoints deviation from the
curve indicates solvation-independent over-oxidation and therefore must be removed from the fit
[213]. MS2 data can be used to identify specific residues that are modified. There are also a few
modifications that can only occur on specific residues, although the majority of modifications, +16
and +14, can occur on 18 and 8 of the 20 amino acids respectively [212, 213]. Modification rates
of peptides can be compared across samples by using a normalization factor [218, 219]. The
normalization factor is determined by measuring the x-ray dose dependent oxidation and decay of
a fluorescent dye, Alexa488 in each of the sample conditions [218].
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In this study we present the hydroxyl radical footprinting of Hsp104 in three states:
monomer, hexamer with ADP and hexamer with ATPγS. We used pepsin proteolysis and mass
spectrometry followed by peptide analysis using a modified version of an HX processing program
called ExMS-CL [220]. We used homology modeled Hsp104 domains, based off the tClpB crystal
structure [102], as a foundation for our examination of the solvation state of each domain in
different nucleotide bound states (see Figure 2 for rigid body fits into the SAXS/WAXS envelope).
Our solvation results allowed us to explain phenomena reported in the literature, to make testable
predictions about the role different regions play in Hsp104 structure and activity and to make a
new mechanistic model of how conformational changes are coupled to substrate remodeling.

3.2

Results

3.2.1

Experimental logic
Samples of the Hsp104 monomer and the Hsp104 hexamer in the presence of either

ADP or ATPγS were exposed to millisecond bursts of synchrotron x-rays and immediately
quenched as described in the methods. On this timescale of hydroxyl radical exposure, the main
reaction products are oxidative modification of the side-chains rather than backbone cleavage or
crosslinking [212, 216]. Using a pepsin column, followed by separation with a C18 column,
Hsp104 peptides were injected into a mass spectrometer as described in methods. Using a
modified version of ExMS [220], an unmodified pool of peptides for each Hsp104 state was
created from four 0 ms timepoint MS/MS runs. Using this unmodified pool, ExMS-CL was used to
search for modified versions of the peptides. The possible modifications vary by amino acid but
have been well characterized [207, 211, 212]. ExMS-CL uses the primary oxidation products for
each amino acid published by Kaur, Kiselar and Chance [213]. Each timepoint (2.5, 5, 7.5, 10,
and 20 ms) was run through MS/MS in triplicate. Using the identification of modified and
unmodified peptides by ExMS-CL and their intensities, Matlab was used to determine the fraction
unmodified for each of the three MS/MS runs for each of the samples timepoints. Only singly
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modified versions of the peptides were used, as further modification is likely to be solventindependent [211, 217]. Additionally, there are often more than one version of the modified
peptide, due to the possibility of multiple types of modification occurring to any given residue, as
well as the ability of many residues within a peptide to become modified (e.g. an entire loop may
be exposed to solvent and contain several residues with approximately equal reactivities, and
each of these can undergo multiple reactions resulting in products of different masses) [207, 212,
213]. Which modification takes place, and which residue it takes place upon, is to some degree
determined stochastically [207, 212, 213]. To circumvent these concerns, each example of the
modified peptide was summed and added to the modified pool when calculating the fraction
unmodified using Matlab. For each timepoint, these values were averaged together and the
standard error determined. Each peptide was binned into one of three categories by the Matlab
program; no time-dependent modification, sporadic modification, and time-dependent
modification. For the peptides that displayed time-dependent modification, the program used the
first four timepoints (0, 2.5, 5, and 7.5 ms) to determine the rate of modification by fitting to a first
order exponential decay. The earliest timepoints were used due to evidence of over-oxidation in
many of the 10 and 20 ms timepoints. Each of the fits was visually checked and manually refitted
using Origin 8.1 when the Matlab program failed to converge onto a visually accurate fit to the
data. If manual re-fitting of the curve was impossible, often due to low signal-to-noise, the peptide
was discarded. There was background modification of many of the peptides, and most of the
sporadically modified peptides when examined manually, did not appear to display any timedependent modification. For those peptides that did display time-dependent modification but were
classified as sporadically modified by the Matlab program, Origin 8.1 was used to manually fit the
curve. In a few cases, there does appear to be time-dependent modification, however, a good fit
to the data was impossible. In those cases the rate of modification is listed as not determined
(ND).
To complement the solvation data from XF, we have also included HD exchange data
generated by Alec Ricciuti in the Englander lab, biochemical data using a variety of techniques,
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and an investigation of the mechanistic basis of mutation based on phenotypes found in the
literature. Finally, we have used the data generated from our hybrid approach to understand local
and global changes of the Hsp104 hexamer during the ATPase cycle and to build a model of how
large conformational changes of the hexamer function to remodel substrate in an ATP-dependent
manner.

3.2.2

Peptide overview
The monomer, hexamer with ADP, and hexamer with ATPγS have 339, 359 and 342

peptides found in all three replicates of all six timepoints, respectively (Table 1). 122 (monomer)
135 (ADP) and 78 (ATPγS) of those peptides showed time-dependent modification, although
several had to be discarded because of irregularities, mostly due to the presence of methionine
residues within the peptide, or poor signal to noise. After discarding suspect peptides we were left
with 81 (monomer), 117 (ADP), and 54 (ATPγS) peptides that showed time-dependent
modification that could be fit to a first order decay curve to yield rate information (Table 1). Tables
2, 3 and 4 list all of the filtered modified and unmodified peptides for the monomer, hexamer with
ADP and hexamer with ATPγS, respectively. In instances where the modified peptide was
selected for fragmentation and MS2 analysis, the identity of the specific site of modification was
determined. The majority of identified peptides are unmodified. For an overall assessment of the
general solvation state, the peptide with the highest rate of modification is used to describe the
rate of modification for all amino acids contained on that peptide. This method of displaying the
data will result in an overestimation of modification rate (and therefore solvation) but this
overestimation will be consistent through and between the three states. This display method
allows us to uncover large changes in solvation between the samples for a given region. For
example, when peptides in one sample show no or very low modification - such as < 1 per
second – while similar peptides in another state show very high rates of modification – such as >
50 per second. For a direct comparison of rates, we need to look at the rate information for the

61	
  
	
  

62	
  
	
  

63	
  
	
  

64	
  
	
  

65	
  
	
  

66	
  
	
  

67	
  
	
  

68	
  
	
  

69	
  
	
  

70	
  
	
  

71	
  
	
  

72	
  
	
  

73	
  
	
  

74	
  
	
  

75	
  
	
  

76	
  
	
  

77	
  
	
  

78	
  
	
  

79	
  
	
  

80	
  
	
  

81	
  
	
  

82	
  
	
  

83	
  
	
  

84	
  
	
  

85	
  
	
  

same peptide for all the states. Table 5 lists identical peptides found in two or three of the states,
which cover some of the regions of interest. The presence of nucleotide in our buffer affects the
effective hydroxyl radical population (i.e. nucleotide quenches the oxidation of the sample).
Therefore, all of the rates have been normalized to the monomer sample based on the Alexa488
decay data [218, 219], with normalization factors of 2.35 and 2.04 for the hexamers with ADP and
ATPγS, respectively.
To begin my analysis of the XF solvation data of the Hsp104 hexamer, and to tease out
relevant mechanistic implications I started by looking at each individual domain. I examined 1)
regions of known functional importance, 2) regions that are heavily modified, and therefore
solvated, and 3) regions that undergo large changes in solvation between states. I then used the
XF data to make mechanistic and structural predictions about regions in each domain. After
investigating each domain separately, I combined the findings to present an overall picture of
changes in solvation in the Hsp104 hexamer and what they mean for its activity and regulation.
3.2.3

The N-terminal domain (NTD)

3.2.3.1 NTD overview
As we learned from Chapter 2, the NTD of Hsp104 is crucial for hexamer cooperativity.
However, details of how it functions remained unclear. The crystal structures of the N-terminal
domains of various Hsp100 proteins, including the Hsp104 bacterial homologues ClpA [141],
ClpB [142], and ClpC [143] have been solved. The NTDs are highly structurally conserved
despite low sequence identity (e.g. 28% sequence identity between the ClpA and ClpB NTDs).
They are very stable globular domains [141] made up of two imperfect repeats of four helical
bundles [141] and are connected to the D1 domain by a highly mobile linker [141]. The repeated
subdomains, R1 and R2, each contain four helices, H1-H4 and H1’-H4’ (Figure 3A). Hsp100
proteins such as ClpA [141] and ClpX [221] contain a zinc binding site in their NTDs. Hsp104
retains the histidine residues involved in zinc [141] binding but not the essential glutamic acid,
while ClpB is missing both the acidic residue as well as one of the histidine residues. A loop
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connecting the two repeats, which in ClpA is highly acidic [141], is instead enriched in glutamines
and prolines in Hsp104. The three glutamines in a row, 78-QQQ-80 are an interesting divergence
from bacterial homologues considering that many yeast prions are asparagine and glutamine rich
[90]. I have homology modeled the Hsp104 NTD based on the NTD of the E. coli ClpB [142]
(Figure 3A, B, D, and E). Support for the accuracy of the Hsp104 NTD homology model, despite
the low sequence identity, is the solvation state of helix H2’ (Figure 3A), residues 113-117. This
helix, based on the homology model, is shielded from solvent, and indeed, a peptide 111-118 that
covers the H2’ helix, while found only in the ATPγS hexamer, is unmodified (Table 4, Figure 3E).

3.2.3.2 The N-terminal domain is involved in substrate binding
When the Hsp104 NTD, homology modeled off the NTD of E. coli ClpB, is compared to
the well-characterized NTD of ClpA [141], there is strong structural homology despite the low
sequence identity (there is 25% and 30% sequence identity between the NTD of Hsp104 and
ClpA or ClpB respectively, similar to the identity between the two bacterial homologues). A
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conserved feature of the Hsp100 NTDs is a hydrophobic patch between H1 and H1’ [141]. We
see that in the homology model of the Hsp104 NTD this hydrophobic patch appears to be
conserved (Figure 3B). Interestingly, the hydrophobic patch region appears to be solvated in all
three states (peptide 86-110, Table 5) and in fact, 4 hydrophobic residues in that region were
identified by MS2 analysis as being specific sites of hydroxyl radical modification (residues A91,
L92, V95, and L96, Table 5, Figure 3C-E). This indicates that this conserved region may have the
capacity to interact with substrate in both the ADP and ATPγS states. Two acidic residues, D108
and D114, which have been implicated in large-aggregate substrate binding in ClpB [150], are
also near the hydrophobic patch. However, in a surface rendering of the domain it appears they
may have only minimal surface exposure, and modification of D108 was only seen in the
monomeric Hsp104 sample (modification of D114 was not seen in any state and the peptide that
covers the area was unmodified in the hexamer with ATPγ).
To test whether the NTD of Hsp104 is involved in substrate binding, we measured the
affinity for a fluorescent substrate, FITC-casein, using a fluorescence polarization assay. We
used the purified wild-type protein (WT) and a truncation mutant (ΔN) missing the NTD as well as
the NTD-NBD1 linker. In the presence of ATPγS WT Hsp104 binds FITC-casein robustly with a Kd
of 55 +- 7 nM (Figure 4A). In the same conditions ΔN Hsp104 binds FITC-casein with a Kd of 194
+- 60 nM, showing a 3 - 4 fold decrease in affinity (Figure 4A). This result supports a role for the
Hsp104 NTD in substrate binding. Mutagenesis studies would allow us to pinpoint specific
residues involved in the substrate interaction. The hydrophobic residues identified through MS2
as being oxidatively modified would be a good starting point. Since the binding surface may
consist of a large, non-specific hydrophobic patch it may be necessary to substitute a number of
residues (there are approximately 10 residues involved in the hydrophobic patch) or replace the
hydrophobic residues with charged residues.
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3.2.3.3 The N-terminal domain is involved in productive interaction with Hsp70
Additional residues that were identified as oxidatively modified by MS2 analysis fall into
two clusters, either A, in the beginning of the H1’ helix and in the H2’-H3’ loop, (residues T87,
Y90, K94, S124, and S125) or C, at the end of H1’ and in the H1’-H2’ loop (residues I102, Q103,
K107 and S109) (Table 1, 3 and 4, Figure 3). These two clusters of residues are in the same
regions that were identified in ClpA to be involved in interactions with an adapter protein ClpS
[141], which protects ClpA from autodegradation and targets ClpA to aggregated substrates
[191]. This was surprising, since the middle domain (MD) of Hsp104 and its bacterial homologue
ClpB have previously been identified as the site of interaction with Hsp70 proteins (the Hsp70
chaperones are essential for in vivo Hsp104 activity) [172-175]. However, in the Hsp100 protein
ClpC, which has a truncated version of the middle domain (motif 1 only) the crystal structure of
the hexamer revealed that the adapter protein MecA made extensive contacts with both the MD
as well as the NTD [143]. This could well be the case for Hsp104 as well, considering that the
region of the MD found to interact with Hsp70, namely residues within motif 2 near the C-terminal
end of helix 2 [178], are adjacent to the NTD in every hexameric model of Hsp104 [171, 222]. The
second cluster of modified residues (C), at the end of H1’, is covered by peptides 99-110 and
100-110 which display a 10-fold protection from HD exchange upon formation of an apo hexamer
(Table 6). An increase in secondary structure upon hexamerization further suggests that the
region may be available for protein-protein interactions, especially since the XF data indicates
that it remains solvated and is therefore unlikely to be involved in a hexamer interface.
Additionally, the residues 100-102 (which contains the oxidatively modified I102, Figure 3C, D)
were identified as a potential Hsp70:Hsp104 binding site using peptide array technology [178],
although the authors did not investigate the region beyond an initial identification. Their dismissal
of the importance of this interaction may have been premature; NTD:Hsp70 interactions,
especially so close to the substrate-binding hydrophobic patch may facilitate substrate release
from Hsp70 for hand-off to Hsp104.
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To test the role of the Hsp104 NTD in productive Hsp70 interaction we used a luciferase
reactivation assay to assess the remodeling activity of WT Hsp104 and ΔN Hsp104 in a variety of
conditions. First, we verified that the ΔN Hsp104 construct was capable of Hsp70-independent
luciferase remodeling. In vitro, in the presence of ATP, Hsp104 is inactive in the absence of
Hsp70/Hsp40 [113]. However, for reasons that are poorly understood, Hsp104 is active in the
absence of Hsp70/Hsp40 by the addition of permissive ratios of ATP:ATPγS [113]. WT Hsp104
has a maximal activity at a 1:1 ratio of ATP:ATPγS (Chapter 2), and at this ratio ΔN Hsp104
displays statistically insignificant differences in luciferase reactivation (Figure 4B). This finding
allowed us to assess defects in productive interactions with Hsp70 proteins, since the inherent
ability of ΔN Hsp104 to remodel aggregated luciferase appeared intact. Keeping the identity of the
Hsp40 protein constant, we used two different Hsp70 proteins, Hsc70, which is constitutively
expressed [223, 224], and Hsp72, which is expressed during heat shock [224]. In the presence of
Hsc70, ΔN Hsp104 retained only 40% WT Hsp104 activity, while in the presence of Hsp72, 86%
(Figure 4B). Reductions in ΔN Hsp104 activity with both Hsc70 and Hsp72 were statistically
significant, with p values of p < 0.02 and p < 0.05 respectively. The difference in activity between
ΔN Hsp104 in the presence of Hsc70 versus Hsp72 indicates that the Hsp104 hexamer may
interact differently (or more or less robustly) with different Hsp70 proteins. Since Hsp104 is overexpressed in response to stress, it may not be surprising that there could be differences in the
productivity of interactions with Hsp70 proteins whose roles vary in vivo (e.g. those whose main
role is in helping nascent polypeptides fold versus those involved in survival during and after
various stresses). Once again, mutagenic analysis would allow us to pinpoint residues directly
involved in these interactions. A promising target is T87, which was identified as oxidatively
modified in the hexamer with ATPγS (Figure 3C, E). This residue is just N-terminal to helix H1’
(Figure 3C, E). In ClpA an equivalent residue, T81, resides within the main ClpS binding site (site
A) [141] and in ClpC the residue T31 has been shown to be essential for ClpC activity by
mediating the interaction with MecA [143]. An alternative possibility would be that the NTD is
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making contacts with the MD, stabilizing the interaction between the MD and Hsp70. Whether
direct, or indirect, it is clear that the NTD plays a role in Hsp70 interaction.

3.2.3.4 The N-terminal domain controls Hsp104 cooperativity through a network of
NTD:NBD1:MD interactions that include the NTD-NBD1 linker
To understand how the NTD may be communicating with neighboring domain(s) and how
these interactions may change depending on the identity of nucleotide, we can first look for
regions that undergo changes in solvation between different states. These regions include the
beginning of helix 1 (residues 8-15), the loop between helix 2 and 3, the loop between helix 3 and
4, and the linker between the NTD and NBD1 (Figure 3C-E). A peptide that covers the beginning
of H1 starting at residue 8, appears to be unmodified in the hexamer with ADP, but has a rate of
-1

1.85 +- 0.33 s in the hexamer with ATPγS (Table 5). The loop between H2 and H3, residues 4151, is covered by the peptide 39-53, which has rates for the ADP and ATPγS hexamers of 25 +-1

0.005 and 4.3 +- 1.5 s , respectively (Table 5). The loop between H3 and H4, residues 58-61, is
covered by the peptide 55-64. This peptide is unmodified in the monomer, and has rates for the
-1

-1

ADP and ATPγS hexamers of 3.6 +- 0.009 s and 0.85 +- 0.18 s , respectively (Table 5).
Additionally, this peptide displayed a 2-fold protection from hydrogen-deuterium exchange in the
hexamer with ADP, and a 10-fold protection in the hexamer with ATPγS (Table 6). The linker
between the NTD and NBD1 is covered by the peptide 148-166 in all three states (Figure 3C-E).
-1

It is unmodified in the hexamer with ATPγS, has a rate of 0.101 +- 0.002 s in the hexamer with
-1

ADP, and 0.215+- 0.014 s in the monomer (Table 5).
Then we can compare these regions from XF to the three tClpB monomer models. In the
crystal structure of tClpB, each monomer of the spiral trimer (designated models A, B and C in
the pdb) has a different orientation of the NTD [102]. By examining the different orientations of the
NTD we discovered regions of the NTD, NBD1, and MD that appeared to be capable of
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interacting in one or all of the three models. The homologous Hsp104 NTD residues include 8-20
found in models A and B, NBD1 residues 264-274 found in models A and C, MD residues 496498 found in models A and C, and NTD residues 39-52, NTD/NBD1 residues 155-169, and NBD1
residues 230-240 found in all three of the models. Many of these regions display changes in
solvation, as mentioned above. These include the beginning of helix 1, residues 8-15 in particular
(Figure 5 in yellow), which are protected from solvation in the hexamer with ADP, the loop
between H2 and H3, residues 39-53 (Figure 5, in orange), which shows a decrease of solvation in
the hexamer with ATPγS, and the NTD-NBD1 linker region, 148-166 which shows a protection
from solvation in the hexamer with ATPγS. If we briefly investigate the regions in NBD1 and the
MD we find that residues 230-240 (Figure 5, in blue) are covered by a number of peptides, which
are always unmodified in both hexameric states (Tables 3 and 4). In fact, the peptide 225-243 is
-1

unmodified in the hexamers while the monomer has a modification rate of 15.9 +- 11.2 s (Table
5). Residues 262-274 display no clear trend in modification rate (Tables 2, 3 and 4), and residues
496-498 (Figure 5, in green), covered by the peptide 494-504 are found unmodified in the
monomer and the hexamer with ATPγS, but the peptide was not found in the hexamer with ADP.
These findings indicate that the NTD, specifically the beginning of helix 1 in the hexamer with
ADP, and the H2-H3 loop and NTD-NBD1 linker in the hexamer with ATPγS may be making a
stable interaction with NBD1, specifically residues 230-240, and potentially the MD, in the loop
between MD helices 2 and 3 in motif 2 (Figure 5). Since we know from Chapter 2 that the NTD is
involved in regulating the ATPase rate and is essential for global cooperativity of the hexamer, we
suggest that these interactions may mediate signals from substrate and/or Hsp70 interactions in
the NTD to the rest of the hexamer. Further support of this model is the fact that an NTD mutant,
T160M, which resides in a region proposed to interact with NBD1 and/or the MD was found to
mimic the NTD deletion phenotype in vivo [154]. Additionally, other regions identified by peptide
array as potential Hsp70 binding sites include residues 34-39 [178], just N-terminal of the H2-H3
loop, and 241-249 [178], just C-terminal of the unmodified 230-240 NBD1 region, indicating that
there may be a complex network of NTD-NBD1-MD:Hsp70 interactions, which the XF solvation
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data has allowed us to map (Figure 5). Mutations in this region, specifically D498V [179], T499D
and I230N (Amber Tariq, Shorter lab unpublished data) lead to potentiated Hsp104 variants, and
deletion of the NTD precludes this potentiation. These findings suggest that this interface is, in
fact, important for hexamer regulation and activity.

3.2.4

Nucleotide-binding domain 1

3.2.4.1 AAA+ motifs
We know from the literature that NBD1 is a high affinity, high turnover site for ATP
binding and hydrolysis [140]. NBD1 is the main site of ATP hydrolysis for the Hsp104 hexamer
[140], but does not drive hexamerization [140]. Since we know that ATP binding and hydrolysis is
required for Hsp104 activity, we wanted to examine changes in solvation of the conserved AAA+
motifs between the hexamer with ADP and hexamer with ATPγS. Overall, the domain is more
modified in the hexamer with ADP than the hexamer with ATPγS (Figure 6A-C), particularly in the
regions involved in the conserved ATP binding pocket. The Walker A motif, residues 212-220, the
Walker B motif, residues 280-285, the sensor-1 residue, T317 and the arginine finger, R334 are
covered by peptides which suggest that in the hexamer with ATPγS the ATP binding pocket is
protected from solvation (Figure 6A). The peptide 211-223 shows no modification in the ATPγS
-1

hexamer, but a rate of 32.6 +- 1.9 s in the hexamer with ADP (Table 5). The peptides 282-299,
283-299 and 286-310 also show no modification in the hexamer with ATPγS but rates of 75 +-1

-1

-1

0.58 s , 28 +- 0.42 s , and 27 +- 0.3 s respectively in the hexamer with ADP (Table 5). The
peptides 300-320 and 311-320, which cover the sensor-1 residue T317, show that the hexamer
-1

with ADP is much more solvated than the hexamer with ATPγS, with rates of 145.6 +- 3.4 s and
-1

-1

2.8 +- 0.03 s for ADP and 0 and 0.37 +- 0.07 s for ATPγS respectively (Table 5). Finally, the
peptides 331-350 and 332-349 that cover the arginine finger R334 are unmodified in the hexamer
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with ATPγS, and have rates of 133.5 +- 3.4 s and 3.8 +- 0.3 s in the hexamer with ADP
respectively (Table 5). Additionally, residues in these regions were identified as modified by MS2
in the hexamer with ADP including the essential Walker B glutamate, residue E285, as well as
R333, the residue directly preceding the arginine finger R334 (Table 5, Figure 6A). A recent
paper from the Tsai lab found that mutation of either R333 or R334 results in a loss of ATPase
activity [225], indicating that both may be involved in the role of arginine finger. These differences
in solvation (Figure 6A) indicate that the six conserved ATP binding pockets of NBD1 in the
hexamer with ATPγS are either all occupied, or all either occupied or closed (i.e. unoccupied, but
shielded from solvent). This observation would fit with hexameric structures of AAA+ proteins
seen to have some sites occupied by nucleotide, and the consequent asymmetric conformational
changes forcing other sites closed [226]. This steric hindrance of all sites binding ATP
simultaneously has been postulated to contribute to substrate handling mechanisms [101, 137,
226]. Regardless of whether the NBD1 nucleotide-binding sites are all bound to ATPγS or some
bound and the rest closed, this situation is clearly not the case for the hexamer with ADP. In the
presence of ADP, there is a large degree of solvation in the nucleotide-binding, which indicates
that either the ADP is either not large enough, or not rigidly bound enough to fully protect the
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participating residues, or that some sites are bound to ADP while others are open and unbound to
nucleotide.

3.2.4.2 Nucleotide-binding domain 1 contains a conserved loop with a potential role in
substrate interaction
Though two substrate-binding loops have been identified in Hsp104 [167], the incomplete
defect in thermotolerance when the NBD1 loop is mutated [167] indicates that there may be
additional regions of NBD1 involved in substrate binding. The canonical substrate binding loop,
256-KYKG-259 [167], is oxidatively modified in both hexameric states, indicating that the loop is
solvated and capable of substrate interaction (Figure 6A-C, Tables 3 and 4). Though rate
information for identical peptides is unavailable for both states, peptides that cover the loop are
have much higher rates of modification in the hexamer with ATPγS than for the hexamer with
-1

-1

ADP (compare 10.6 +-5.3 s and 18.2 +- 0.37 s for peptides from the hexamer with ATPγS to
-1

-1

0.51 +-0.12 s and 1.15 +- 0.08 s for peptides from the hexamer with ADP - Tables 3 and 4). As
the Hsp104 hexamer primarily binds substrate in the ATP state [204, 227], it is unsurprising that
the loop would be more exposed in the hexamer with ATPγS than in the hexamer with ADP.
While Y257 has been identified as one of two substrate binding residues in Hsp104,
thermotolerance assays show that mutation of the tyrosine to alanine results in only minor defects
in Hsp104 mediated survival [167]. This is in contrast to mutation of the NBD2 tyrosine, Y662 to
alanine, which results in large defects in survival after heat shock [167]. This finding led us to
hypothesize that regions of the NTD as well as other sites within NBD1 may also contribute to
substrate binding. As discussed in the preceding section, the NTD is indeed involved in substrate
binding (Figure 4A). This finding is further supported by thermotolerance data showing that while
either deletion of the NTD or mutation of Y257 display only mild defects in thermotolerance, the
combined truncation and mutation variant, ΔN:Y257A Hsp104 is severely compromised in its
ability to mediate survival after heat shock (Figure 7A). To determine if there are other substrate
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binding regions of NBD1 we looked for regions that change in solvation in the different hexamers.
A striking example stood out immediately. In the homology model of the Hsp104 NBD1 there are
two loops that point into what would be the interior of the hexameric Hsp104 channel (Figure 6AC). One is the canonical 256-KYKG-259 loop and the second is the 291-GNGKD-295 loop.
Peptides covering the 291-GNGKD-295 loop are unmodified in the hexamer with ATPγS, but
highly modified in the hexamer with ADP (the peptides that cover the Walker B site also cover this
loop) (Figure 6A-C, Table 5). In addition to the peptides (282-299, 283-299 and 286-310, Table 5)
-1

-1

displaying high rates of modification in the hexamer with ADP (75 +- 0.58 s , 28 +- 0.42 s , and
-1

27 +- 0.3 s , respectively, Table 5) three residues within and near the 291-GNGKD-295 loop
were identified as modified by MS2, including N292, and K294 (Figure 6A). This loop is
homologous to the ClpC 286-GAGGA-290 [143] loop, as well as the ClpA 292-GAGAA-296 [168]
loop, which are secondary substrate binding loops. Mutation or deletion of this loop results in
severe defects in ClpC [143] and ClpA [168] activity.
We decided to test our hypothesis that this loop is involved in substrate processing in
Hsp104. To assess whether this loop is actually necessary for Hsp104 activity, we carried out in
vivo thermotolerance and in vitro luciferase reactivation assays, as well as fluorescence
polarization assays to test for differences in Kds. Fluorescence polarization experiments revealed
that mutations in the loop, N292A, K294A and D295A, had no statistically significant effect on
FITC-casein binding in the presence of ATPγS (Table 7). This result was to be expected since the
loop appears to be protected from solvent in the hexamer with ATPγS, and is therefore unlikely to
interact with substrate in this state. Since initial and robust substrate binding appears to occur in
the Hsp104 hexamer with ATP, one possibility is that this second loop transiently engages the
substrate during or after ATP hydrolysis to ADP. This interaction could prevent substrate diffusion
as the subunits in the hexamer rebind ATP and subsequently reengage the polypeptide at a new
site, thereby driving directional translocation of the substrate. We decided to test whether there
were differences in FITC-casein binding in the presence of ADP. WT Hsp104 binds FITC-casein
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in the presence of ADP with a Kd of 5.9 +- 0.7 µM, 2 orders of magnitude weaker than in the
presence of ATPγS. When we tested our loop mutants, we found that once again there were no
statistically significant changes in affinity (Table 7). And this may not be surprising. If our model is
correct, substrate would first need to engage the Hsp104 hexamer in the presence of ATPγS, and
then be handed off to the second loop. In our experimental set-up the Hsp104 hexamer is
incubated with ADP and then FITC-casein is added. In these conditions we may not expect
substrate to bind in a manner indicative of how the Hsp104 hexamer normally processes
substrate.
In vivo thermotolerance assays revealed that the K294A Hsp104 variant displayed a
slight, but statistically significant (p=0.05), defect in mediating survival after heat shock compared
to WT Hsp104 (Figure 7A, work of Michelle Go, Shorter lab). When the K294A mutation was
combined with the NTD truncation, survival after heat shock was similar to the ΔN:Y257A variant
(Figure 7A, work of Michelle Go, Shorter lab). The double mutant Y257A:K294A variant was less
active than the single mutants, but more active than the single mutants combined with the NTD
truncation (Figure 7A, work of Michelle Go, Shorter lab). This in vivo data supports a role for the
loop in substrate processing. We then wanted to test the mutants in an in vitro assay with minimal
components so that we could remove the confounding and potentially mitigating effects of the
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presence of various Hsp70 and other chaperone proteins. To test the activity of the loop mutants
in a minimal component situation, we carried out luciferase reactivation assays in the presence of
a 1:1 ratio of ATP:ATPγS. What we found was that the loop mutants N292A, K294A and D295A
were defective in luciferase reactivation, retaining only 20%, 39% and 19% of WT Hsp104
respectively (Figure 7B). This finding confirmed the importance of this loop for productive
substrate remodeling, and indicates that defects caused by mutations in the loop can, in fact, be
partially mitigated by the in vivo environment. Ideally we would be able to test whether our
proposed mechanism for the loop, preventing substrate diffusion as subunits rebind ATP, is
correct. An assay designed to measure release of substrate due to ATP hydrolysis after initial
binding events would be able to confirm whether mutations in the loop result in more, or faster
release of substrate. An alternative would be to measure processivity of the WT and mutant
Hsp104 variants.

3.2.5

Solvation of the middle domain changes dramatically in the presence of different

nucleotides, which supports a role in Hsp104 regulation
We aimed to use information from the literature as well as our solvation data from the XF
experiments to get a holistic understanding of how local and global dynamics of the MD
determine its role in regulating the hexamer. The homology model of Hsp104’s anti-parallel
coiled-coil middle domain (MD), based off of the tClpB structure, retains the leucine zipper-like
interactions between the helices 1-4 (Figure 8B and C). The arrangement of large hydrophobic
residues such as leucine and isoleucines at the helical interfaces, with polar and charged
residues exposed on the other side of the helices, is an indication that the model is sound.
Additionally, hydrogen-deuterium exchange experiments confirm the loop-secondary structure
boundaries (data not shown, Alec Ricciuti and Walter Englander manuscript in preparation). The
MD has been implicated in regulating the ATPase rate and activity of the hexamer [136, 145, 172,
173, 175-177, 228-230], transmitting signals between NBD1 and NBD2 [181, 228, 229], and
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mediating the interaction with Hsp70 [172-175, 178]. Interactions with Hsp70 proteins have
shown to take place in motif 2, specifically residues 480-KKK-482 and residue R496 [178]. We
have already discussed in the preceding sections how these regions are poised to interact with
the NTD as well as NBD1 (Figure 5). In ClpB a number of interactions between motif 2 of the MD
and NBD1 have been identified [102, 172, 176, 231] and it has been shown that stabilization of
these interactions leads to repression of the disaggregase [102, 172, 176], while destabilization
leads to potentiation [102, 176, 179, 231]. While the models in Figure 8 show the MD partially
projecting into solution, it is simply representative of one possible orientation. XF data as well as
published crosslinking [176, 222] and structural data [176] support a model in which the domain is
highly mobile, undergoing interactions with both NBD1 [102, 172, 176, 231] and NBD2 [222].
Additionally, it is likely that MDs within a given Hsp104 hexamer occupy a variety of positions
[176]. The orientation shown in Figure 8 is fit into a symmetrically averaged volume envelope,
and future work would include modeling the domain asymmetrically into the hexamer in a variety
of positions based on a compilation of the published data and XF information
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XF data of the MD shows large changes in solvation between the hexamer bound to
ADP and the hexamer bound to ATPγS (Figure 8A-E). This finding is to be expected since the
domain is highly dynamic, and restricting its movement through disulfide crosslinking greatly
impairs Hsp104 activity [102, 172, 222]. In general, the hexamer with ADP displays greater
solvation than the hexamer with ATPγS (Figure 8A-E, Tables 3-5). The only part of the MD where
this is not true is the first three residues of the MD, 412-414, found on the peptide 405-414, which
mainly covers the NBD1 domain (Table 5). This peptide is solvated in both hexameric states, but
-1

-1

more so in the presence of ATPγS (compare 21.5 +- 0.4 s to 52.8 +- 9.5 s , Table 5).
Modification rates change at the adjacent peptide. The peptide 415-423 shows that the hexamer
with ATPγS is unmodified while the hexamer with ADP has a modification rate of 35.5 +- 0.8 s

-1

and contains several residues identified as modified by MS2: D415, S416, K417, E418, L421 and
L423 (Table 5, Figure 8A).
This peptide covers the first half of helix 1, and is adjacent to a region of helix 2, residues
456-466, which is also unmodified in the hexamer with ATPγS (Figure 8C, see arrows). This
-1

peptide, 456-466, has a modification rate of 1.8 +- 0.5 s in the hexamer with ADP and contains
residues identified as modified by MS2, E457 and E460 (Table 5, Figure 8A). A region more Cterminal in helix 2, residues 467-474, is unmodified in the hexamer with ADP, but is modified in
the hexamer with ATPγS. A peptide that covers this region, 467-493, is unmodified in the
-1

hexamer with ADP, and has a modification rate of 0.84 +- 0.1 s in the hexamer with ATPγS
(Table 5). Interestingly, the same peptide shows large changes in protection from deuterium
exchange. From monomer to apo hexamer to hexamer with ADP to hexamer with ATPγS the
peptide undergoes increases in protection from 2- to 10- to 50-fold respectively (Table 6, Alec
Ricciuti). The changes in solvation and secondary structure indicate that transitions in this region
of helix 2 may play a role in transmission of conformational changes from motif 1 to motif 2 in
response to stimuli (e.g., interaction with Hsp70, binding of substrate in the NTD and NBD1, and
ATP hydrolysis at NBD1 or NBD2). It’s been shown that the MD is crucial for communication
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between NBD1 and NBD2 [181, 228, 229], for example, in ClpB ATP binding in NBD1 leads to
large movements of the MD and subsequently promotes hydrolysis in NBD2 [229] (this
communication route may be reversed in Hsp104 since the role of the two nucleotide binding
domains is transposed between ClpB and Hsp104 [135], or could be bi-directional). Additionally,
a mutation in this region, L462R, was discovered to disrupt intersubunit cooperativity [132],
suggesting that this region is critical for communication within the Hsp104 hexamer.
Several crosslinks between motif 2 of the MD and NBD1 have been found, in ClpB:
G175C:S499C [172], D178C:S499C [172], G167C:R475C[102], V350C:Q467C[102],
G353C:R464C[102], R355C:E520C[102], K476C:E358C[176] and in Hsp104 there may be a salt
bridge D484:D184:K358 [231]. Models proposing that this motif 2-NBD1 interaction is dynamic
are supported by the solvation data which shows large increases in solvation in the hexamer with
ADP compared to the hexamer with ATPγS (Figure 8A-E). These increases in solvation include
the C-terminal end of helix 2 (Tables 3 and 4) as well as the end of helix 3 through the end of the
MD (peptides 505-526, 506-522, and 508-536 with rates for the hexamer with ADP of 350 +- 0.9
-1

-1

-1

-1

-1

s , 20 +-1.2 s , and 89 +- 3.4 s respectively versus 0 s , 1.5 +- 1 s , and undetermined for the
hexamer with ATPγS) (Table 5). Residues 494-504 are not found in the hexamer with ADP but
are unmodified in the hexamer with ATPγS. This finding indicates that helices three and four of
motif 2 are partially shielded from solvent in hexamer bound to ATPγS. If this protection from
solvent is representative of the repressive motif 2-NBD1 contacts it would support a model where
the repressed state of the hexamer is predominantly found in the hexamer with ATPγS. This
would make sense since ATP hydrolysis is necessary for substrate remodeling. Additionally,
several potentiating mutations are found in helices 3 and 4 [102, 176, 179, 231] (Dr. Meredith
Jackrel, unpublished work), indicating that large changes in solvation between nucleotide bound
states may indicate mechanistically important regions of the Hsp104 hexamer.
More recent work in our lab uncovered robust crosslinks between motif 1 of the MD and
NBD2, A430C:F630C, and K451C:E790C [222] and mutations in the distal loop (R433-R441)
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revealed that the region is crucial for transmission of Hsp70-mediated relief of the MD
autoinhibition [222]. These crosslinks were predicted by a hexameric Hsp104 model in which the
MD is intercalated between the NBDs [136, 137]. Confirmation of these crosslinks means that the
MD cannot invariably project into solution as proposed in a second hexameric model of Hsp104
[171]. The XF data shows that the distal loop is more solvated in the hexamer with ADP than the
-1

hexamer with ATPγS (peptide 431-455 with rates of 0.57 +- 0.009 s and 0.08 +- 0.05 s

-1

respectively, Table 5) and that the region around residue 630 is also more solvated in the
-1

hexamer with ADP than the hexamer with ATPγS (peptide 611-631 with rates of 4.9 +- 2.2 s and
-1

0 s respectively, Table 5). Peptides covering the NBD2 residue involved in the second crosslink
are similar, with rates for the hexamer with ADP much higher than for the hexamer with ATPγS
(peptides 789-806 and 789-809 which are unmodified in the hexamer with ATPγS but have rates
-1

-1

of 22.3 +- 0.3 s and 20 +- 0.2 s respectively for the hexamer with ADP, Table 5). All of these
XF modification rates match the crosslinking data well, since the crosslink was most robust with
AMP-PNP, less so with ATP, and even less with ADP [222]. Therefore, data from multiple
techniques confirms that the interactions of the MD and NBD2 are stabilized in the hexamer with
ATPγS compared to the hexamer with ADP. These motif 1 MD-NBD2 crosslinks reveal a missing
piece to the NBD1-MD-NBD2 communication network, and the changes in solvation and
secondary structure at the juncture of motif 1 and motif 2 found by XF and hydrogen deuterium
exchange explains how signals may be transmitted through the coiled-coil between the two
nucleotide binding domains in response to ATP hydrolysis and Hsp70 binding.

3.2.6

Nucleotide-binding domain 2

3.2.6.1 AAA+ motifs
First, we will examine modification of the conserved NBD2 ATP binding motifs as well as
the region that contains the nuclear localization signal (NLS) [157]. There is no coverage of either
the arginine finger or the sensor 1 residue. Similarly to our findings in NBD1, a peptide 684-697
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that covers the Walker B motif is unmodified in the hexamer with ATPγS but has a rate of 49 +-1

1.3 s and two residues identified by MS2 as being modified, L684, and the conserved glutamate,
E687 in the hexamer with ADP (Table 5). Additionally, the peptide 813-831 that covers the sensor
-1

2 residue (R826), is unmodified in the hexamer with ATPγS and has a rate of 42 +- 0.2 s in the
hexamer with ADP (Table 5). However, just C-terminal of the Walker B motif is a peptide 688-1

696, which in the hexamer with ATPγS has a modification rate of 57 +- 9.4 s , and a peptide 613-1

623 which covers the Walker A motif has a rate of 9.5 +- 0.3 s in the hexamer with ATPγS with
residues 616 and 618 have been identified by MS2 as modified (Tables 4 and 5). These data
indicate that in contrast to NBD1, ATPγS binding in NBD2 does not fully shield the nucleotidebinding pocket from solvent. This may be due to the presence of empty, incompletely closed
sites, and/or less stable ATPγS binding, which would result in partial solvation of some of the
sites with the Hsp104 hexamer population. Differences between NBD1 and NBD2 are not
surprising, as they belong to different AAA+ clades [155] and are responsible for divergent
functions within the Hsp104 hexamer [140].

3.2.6.2 Nucleotide-binding domain 2 nuclear localization signal (NLS)
The NLS in Hsp104, residues 773-789 [157], appears to be solvated in the monomer as
well as both of the hexameric states, with the hexamer with ATPγS the least modified (Table 5,
Figure 9). The NLS also includes the NBD2 hinge 773-NKLS-776, which connects the large and
small subdomains of NBD2. Peptides that cover this regions include 769-785 and 786-806 with
-1

rates for the monomer, the hexamer with ADP and the hexamer with ATPγS of 1.15 +- 0.1 s ,
-1

-1

-1

-1

0.64 +- 0.003 s , and 0.14 +- 0.02 s respectively for 769-785 and 0 s , 17.6 +- 6.3 s , and 0 s

-1

respectively for 786-806 (Table 5). There are many MS2 identified modified residues in this
region, including lysines (in bold) which, when all mutated to alanine result in a loss of nuclear
accumulation [157], as well as residues (in italics) that are in the NBD2 hinge. K774 may or may
not be necessary for nuclear localization; since it is in the NBD2 hinge mutating it to alanine
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disrupts the protein’s stability. The MS2 identified residues include (all found on the peptide 769785): N773, K774, S776, K778, A779, I780, H781, K782, and V784 in the monomer, F772 (just
before NLS), K774, H781, K782, I783, V784 found in the hexamer with ADP, and F772, K774,
S776, R777, I780, K782 found in the hexamer with ATPγS (Table 5, Figure 9). It would appear
that K782 is always exposed to solvent, and in the monomeric state the hinge is highly exposed
(3 of 4 NBD2 hinge residues were identified as modified, compared to the hexamer with ATPγS (2
of 4) and the hexamer with ADP (1 of 4)). The third essential lysine, K789 [157] is not on the
peptide 769-785 and therefore we have not confirmed its solvation state.

3.2.6.3 A hexameric model of nucleotide-binding domain 2 which is consistent with the XF
solvation data
The second nucleotide-binding domain (NBD2) is necessary and sufficient for Hsp104
hexamerization [160], however, a hexameric interface has yet to be described. We have used the
monomeric NBD2 modeled off of the tClpB structure to create a hexameric NBD2 model (Figure
9B and C). This model uses the equivalent subunit:subunit interfaces seen in the hexameric ClpC
[143] and ClpX [226] structures, and fits previously published crosslinking [225] and mutational
data [182]. This interface includes helix 3 and part of its C-terminal loop in the large NBD2
subdomain (residues 586-AIKAVSNAVRLSRSGL-601, with conserved hydrophobic residues in
bold), and the last helix and part of its C-terminal loop in the neighboring NBD2 small subdomain
(residues 836-ILNKLALRILKNEI-849, with conserved hydrophobic residues in bold) (Figure 9).
There are a large number of conserved, hydrophobic residues in these regions indicating
that they may be mediating the subunit:subunit interaction. If the subunit:subunit interaction was
driven by hydrophobic interactions, it would explain a number of previously published
phenomena. We know that the protomer interface undergoes large changes in conformation
during the functional cycle of the hexamer; crosslinking the small and large subdomains results in
stable hexamers with diminished function [225]. If the interface was a rigid salt bridge, it may
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hinder rapid and smooth movements of the domains. If instead the region were a network of
hydrophobic residues then the interface could easy change register upon conformational changes
of nearby regions. The proposed interface is ideally suited to respond to changes in nucleotide –
while the C-terminal end of the small NBD2 helix contains a number of conserved hydrophobic
residues that we propose to be involved in the hexamer interface, the N-terminal end contains a
region called the sensor and substrate discrimination (SSD) motif, which contains a sensor 2
arginine (R826) [102] (Figure 9). Additionally, the helix and loop in the NBD2 large domain that
we propose to be involved in the interface is just N-terminal to a short, highly conserved β-sheet
that immediately precedes the conserved Walker A motif [102].
A hydrophobic interface would also explain why the Hsp104 hexamer is sensitive to salt
[140]. As salt concentrations increase, the Hsp104 hexamer becomes destabilized [140]. Upon
cursory inspection, this finding would make it seem unlikely that the interface were mediated by
hydrophobic interactions, however, Hsp104 undergoes continual and rapid monomer exchange
[132]. Upon mixing Hsp104 hexamers with different (measurable) properties, monomer exchange
occurs on a timescale of just a few minutes to yield an ensemble of hexamers containing subunits
of different Hsp104 variants explained by the binomial distribution [132]. This phenomena of
monomer exchange explains why high salt conditions would disrupt hexamer integrity, as a
monomer is released from the hexamer into high salt conditions, there will be a propensity to
make intramolecular contacts in order to bury the newly exposed hydrophobic hexamer interface.
We find support for this hypothesis by examining the solvation information from the XF
modification data. In the monomeric sample, which was created by adding 500 mM NaCl to the
buffer, there are two regions, one N-terminal to helix 3 of the large NBD2 domain (residues 569583), and one C-terminal of the small NBD2 domain helix (residues 843-857), which become
shielded from solvent (Figure 10A, Table 2). Though there is no coverage of 569-583 in the
hexamer with ATPγS, it is highly modified in the hexamer with ADP (Tables 3 and 4). The peptide
843-857 is unmodified in the monomer and modified in both of the hexamers, with a number of
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residues identified as modified by MS2 (3.8 +- 0.14 s with residues R843, K850, E853, and
-1

V855 for the hexamer with ADP and 6.1 +- 4.5 s with residues R843, L845, K846, E848, I849,
K850, K852, and V857 for the hexamer with ATPγS, Table 5). Both of these regions also contain
highly conserved hydrophobic residues [102], supporting the possibility that they may be involved
in intramolecular interactions that block hexamerization in high salt.
We decided to test whether we could disrupt the hexameric interactions by mutating a
conserved hydrophobic residue in the proposed protomer interface to a charged residue. We
chose L601 because it is in a loop region, so it was unlikely to grossly perturb secondary
structure, and it is conserved in Hsp100 proteins from plants to bacteria to yeast [102]. Using a
glutaraldehyde crosslinking assay [160] we assessed the ability of low concentrations of WT
Hsp104, the double Walker A mutant (DWA - a variant known to severely disrupt hexamerization
[160]) and a L601K variant to form hexamers under two conditions, adding either EDTA or ATP.
Addition of EDTA chelates the magnesium essential for ATP binding and therefore disrupts the
ability of Hsp104 to form hexamers, while addition of ATP promotes the formation of hexamers
[139]. We visualized the gels using silver stain and found that WT Hsp104 exists as a mixture of
monomer, dimer, trimer and hexamer in the presence of EDTA, and upon addition of ATP shifts
entirely to the hexamer (Figure 11). DWA Hsp104, our negative control, shows very little hexamer
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in the presence of EDTA, and upon addition of ATP remains a mixture of monomer, dimer and
trimer (Figure 11). The L601K Hsp104 mutant appears to strongly resemble the DWA Hsp104
variant; even upon addition of ATP there is very little hexamer but instead mostly smaller
oligomers and monomer (Figure 11). This data supports the potential placement of the residue
near a hydrophobic hexamer interface. Future experiments include repairing the interface with a
compensatory, oppositely charged residue in the small NBD2 domain, as well as disulfide
crosslinking.
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Once I had a proposed interface and hexameric model, I used the XF modification rate
information to assess its validity. I have colored the NBD2 hexameric model based on the XF
modification rates for the hexamer with ADP as well as the hexamer with ATPγS (Figure 10B and
C). Despite large differences in solvation, both of the states agree well overall with the model
(Figure 10B and C). The hexamer with ADP shows a high degree of modification, with only two
regions that appear to be shielded from solvation. These regions include residues 646-670 which
contain the canonical substrate binding motif 661-GYVG-664, as well as residues 838-NKLAL842, which reside within the region of the NBD2 small domain we propose to be involved in the
hexamer interface (Table 3, Figure 10A). The fact that the rest of the domain appears to be
solvated fits with the overall trend we have seen in both the XF solvation data and the HD
exchange data, namely that the hexamer with ADP has less structure and more regions
accessible to solvent. This suggests a model in which the energy of ATP binding induces the
formation of stable secondary structure as well as minimizing large dynamic movements which
would, due to the ensemble nature of XF experiments, result in increased regions of solvent
accessibility. The implications for this finding will be explored further in a subsequent section. The
hexamer with ATPγS has a number of regions that appear to have decreased modification rates
and therefore solvation when compared to the hexamer with ADP (Figure 10A-C). When the
modification rates are mapped onto our hexameric model we see a striking agreement (Figure
10B and C). Regions that display no oxidative modification include the core of the globular NBD2
domains, which in contrast to the hexamer with ADP, indicates that in the presence of ATPγS the
domain is rigid, thereby protecting the interior of the domain from solvent. The substrate binding
region is also unmodified in the hexamer with ATPγS, indicating that hydrolysis in NBD1 may be
necessary to prime the GYVG loop for substrate engagement (Table 4). There is also substantial
protection of the regions we believe to be involved in the hexamer interface. Though there is no
coverage of the N-terminal part of the NBD2 large subdomain helix, residues in the middle show
no modification, while residues on the helix near the surface of the hexamer show a low rate of
-1

modification (peptide 597-610 with a rate of 0.45 +- 0.17 s , Table 4). Similarly, the NBD2 small
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subdomain helix is unmodified in the N-terminal end, which is the interior of the hexamer, while
modifications increase C-terminally. The region of the helix positioned near the outside of the
hexamer becomes increasingly modified (peptides 838-856 and 843-857 with rates of 0.12 +-1

-1

0.009 s and 6.12 +- 4.5 s respectively, Tables 4 and 5).

3.2.7

C-terminal domain
Hsp104 has a unique C-terminal extension (CTD). The role of the CTD is poorly

understood, though it is required for hexamerization [180, 182]. The XF data revealed a
surprisingly unmodified stretch of acidic residues in the C-terminal extension (CTD), residues
893-GDDDNEDS-900 (Table 4, Figure 10A). The protection of this acidic patch, predicted to be
unstructured, may be an important clue to its role, however, since the region is unique and
therefore cannot be modeled based off homology it is hard to predict where it might be interacting
with the rest of the hexamer. One possibility is a region of low homology in the NBD2 large
domain helices 10 and 11 [102], which is protected in the hexamer with ATPγS (peptides 733-744
-1

and 733-748 are unmodified in the hexamer with ATPγS and have rates of 1.8 +-0.02 s and 103
-1

+- 3 s respectively in the hexamer with ADP). In Hsp104 this region has a large number of polar
residues as well as two lysine residues. Whether the two regions interact could be tested using
disulfide crosslinking.

3.2.8

Overall changes in solvation and hydrogen-deuterium exchange supports a new

model for substrate remodeling by Hsp104
Overall, the hexamer with ADP shows more modification in our XF experiments as well
as more HD exchange than the hexamer with ATPγS (Tables 2-6). These findings indicate that
the hexamer with ADP is more solvated and has less secondary structure than the hexamer with
ATPγS. It would appear that ATP binding induces global increases in secondary structure and
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protection from solvent. This protection from solvent is likely due to decreases in local and global
dynamics as increases in secondary structure rigidify the hexamer. This increase in rigidity can
be thought of as a pre-payment of the entropic cost of substrate binding. This may have important
implications for discrimination between soluble and aggregate substrates. When binding a large,
stable aggregate, the main entropic penalty would come from decreases in mobility of the Hsp104
hexamer. Conversely, when binding soluble, potentially properly folded substrates, the main
entropic penalty would come from the substrate. This mechanism of rigidifying the hexamer in
preparation for substrate binding could contribute to discriminating between aggregated
substrates, and soluble proteins that could, but should not, be remodeled. We have shown
through our XF data as well as FITC-casein binding assays that substrate binds in the NTD and
NBD1 domains. In the rigid, low entropy state the NTD and NBD1 are poised for substrate
binding and the MD is in a configuration where motif 2 is making interactions with the NTD and
NBD1 while motif 1 is making repressive contacts with NBD2 [222]. As substrate binding occurs
at the NTD and NBD1, and/or Hsp70 binds at the MD/NTD interface, a cascade of events is
triggered which relieves inhibition and allows substrate remodeling to commence. Substrate
binding may trigger ATP hydrolysis in NBD1, as is seen in ClpB [232], or it may occur randomly.
Whichever the case, hydrolysis of ATP results in a loss of rigidity of helix 2 of the MD, which
results in loss of the repressive MD-NBD2 contact [222]. This allows signal transmission between
NTD/NBD1 and NBD2 and may coordinate cooperativity. Our XF data shows us that the
nucleotide-binding sites in NBD2 are only partially filled in the hexamer with ATPγS, and some
may be open and unoccupied (in contrast to the nucleotide binding sites in NBD1 which are either
all full or closed in the hexamer with ADP). Upon initial ATP hydrolysis at NBD1 and relief of the
MD-NBD2 repression, nucleotide binding may occur more robustly in NBD2. Nucleotide binding
at NBD2 stimulates hydrolysis in NBD1 [140], and therefore fully activates the Hsp104 hexamer.
As ATP is hydrolyzed, the secondary substrate-binding loop, which we identified in our XF study,
becomes positioned to engage substrate, potentially to prevent diffusion. The channel of the
Hsp104 hexamer collapses, making a peristaltic pump motion N- C-terminally (Chapter 2).
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Substrate can be engaged in NBD2 as channel collapse and NBD1 loop movements pull
substrate C-terminally. NBD1 exchanges ADP for ATP while the secondary substrate-binding
loop prevents substrate diffusion, and the NTD and NBD1 reengage the substrate higher up.
Once the hexamer has been engaged, iterative rounds of these actions results in remodeled
substrates.

3.3

Conclusions
In this chapter we have identified, from XF oxidative modification data, 1) Regions in the

NTD likely to be involved in substrate and Hsp70 binding, 2) Novel sites of NTD:NBD1:MD
interaction which may mediate cooperativity of the hexamer for which the NTD is essential, 3) A
loop in NBD1 that may engage substrate in the ADP bound state to prevent substrate diffusion as
ADP is exchanged for ATP, 4) The region of the MD (helix 2) responsible and the mechanism of
signal transmission between NBD1 and NBD2, 5) Confirmed the validity of a hexameric model of
the NBD2 domain, 6) Proposed a comprehensive model for the mechanism of Hsp104 substrate
remodeling, and 7) Identified regions and specific residues in all of the Hsp104 domains which
may play important roles for the hexamer, allowing the field to make directed changes in Hsp104
sequence rather than rely solely on random mutagenesis for the production of Hsp104 variants
with altered activities. Our XF findings were supported using HD exchange (Alec Ricciuti,
Englander lab), biochemical assays to confirm the importance of the NTD for substrate binding
and productive Hsp70 interaction, in vivo and in vitro assays to confirm the importance of the
novel NBD1 loop in substrate processing, and crosslinking studies to determine the MD:NBD2
interaction[222] and the importance of hydrophobic residues in the hexamer interface.
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Chapter 4:

4.1

Conclusions and future directions

Conclusions
We have used a hybrid approach, applying several structural and biochemical

techniques, to elucidate novel details of the structure of the Hsp104 hexamer and its mechanism
of substrate remodeling. In Chapter 2, we set out to determine the role of the Hsp104 N-terminal
domain (NTD) and to visualize large conformational changes of the hexamer using small and
wide-angle x-ray scattering (SAXS/WAXS). In Chapter 3, we used an in solution technique, x-ray
footprinting (XF), that directly probes the solvation state of the Hsp104 hexamer in the presence
of different nucleotides. The changes in solvation allowed us to make predictions about what
these conformational changes mean for the individual domains, the Hsp104 hexamer as a whole,
and the mechanism of substrate remodeling. We complemented the XF data with biochemical
techniques, and were able to elucidate novel insights into substrate binding and processing,
interaction with Hsp70, movements of the coiled-coil middle domain, and the subunit:subunit
interface. By combining data from throughout the thesis we were able to propose a model of how
Hsp104 is activated and remodels substrate.
In Chapter 2 we found that the Hsp104 NTD is necessary for nucleotide-dependent
conformational changes that allow productive hexamer cooperativity. Cooperativity is dispensable
for disordered aggregate dissolution, but necessary for robust and adaptable hexamer function
[132]. This deficiency in hexamer cooperativity results in a deregulated ATPase rate, diminished
unfoldase and tranlocase activity, and an inability to remodel exceptionally stable substrates such
as amyloid, even in the presence of potentiating mutations. By examining the role of the Nterminal domain, we also discovered details about the WT Hsp104 hexamer. From our
SAXS/WAXS studies in Chapter 2 we found that the Hsp104 channel undergoes peristaltic pumplike motions, which would facilitate directional movement of substrate through the central channel.
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We have also discovered that partial unfolding of substrate can be sufficient for aggregate
dissolution.
In Chapter 3 we used XF data to determine changes in solvation between Hsp104
hexamers bound to different nucleotides, and complemented our XF findings with biochemical
assays. We found regions in the NTD likely to be involved in substrate and Hsp70 binding, and
identified novel sites of NTD:NBD1:MD interaction, which may mediate cooperativity of the
hexamer. We discovered a loop in NBD1 that may engage substrate in the ADP bound state to
prevent substrate diffusion as ADP is exchanged for ATP. We determined the region of the MD
(residues ~455-475 in helix 2) likely to be responsible for signal transmission between NBD1 and
NBD2, and proposed a mechanism of transmission. We confirmed the validity of a hexameric
model of the NBD2 domain we proposed based on published Hsp100 hexameric crystal
structures. We proposed a comprehensive model for the mechanism of Hsp104 substrate
remodeling and finally, we identified regions and specific residues in all of the Hsp104 domains
that may play important roles for the hexamer. Identification of these regions will allow us to make
directed changes in Hsp104 sequence rather than rely solely on random mutagenesis for
production of Hsp104 variants with altered activities.
By combining our findings we propose a comprehensive model of the mechanism of
Hsp104 substrate remodeling (Figure 1). Our findings indicate that ATP binding induces global
increases in secondary structure and protection from solvent. This protection from solvent is likely
due to decreases in local and global dynamics as increases in secondary structure rigidify the
hexamer. Since Hsp104 engages substrate in the ATP-bound state, the rigidity of the hexamer
with ATP can be thought of as a pre-payment of the entropic cost of substrate binding, especially
since the entropic cost of binding to a large, insoluble aggregate would be paid primarily by the
Hsp104 hexamer. In the rigid, low entropy state the NTD and NBD1 are poised for substrate
binding and the MD is in a configuration where motif 2 is making interactions with the NTD and
NBD1 while motif 1 is making repressive contacts with NBD2. As substrate binding occurs at the
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NTD and NBD1, or Hsp70 binds at the MD/NTD interface, or both, a cascade of events is
triggered which relieves inhibition and allows substrate remodeling to commence. This step can
be thought of as ‘priming the pump’, or allowing the hexamer to unleash its auto-inhibited
remodeling activity. Substrate binding may trigger ATP hydrolysis in NBD1, as is seen in ClpB
[232], or it may occur randomly. Whichever the case, hydrolysis of ATP results in a loss of rigidity
of helix 2 of the MD, which results in loss of the repressive MD-NBD2 contact [222]. This allows
signal transmission between NTD/NBD1 and NBD2 and may coordinate cooperativity. Our XF
data shows us that the nucleotide-binding sites in NBD2 are only partially filled in the hexamer
with ATPγS, and some may be open and unoccupied (in contrast to the nucleotide binding sites in
NBD1 which are either all full or closed in the hexamer with ATPγS). Upon initial ATP hydrolysis
at NBD1 and relief of the MD-NBD2 repression, nucleotide binding may occur more robustly in
NBD2. Nucleotide binding at NBD2 stimulates hydrolysis in NBD1 [140], and therefore fully
activates the Hsp104 hexamer. This positive feedback loop allows the hexamer to transition from
a repressed state to an active state. As ATP is hydrolyzed, the secondary substrate-binding loop,
which we identified in our XF study, becomes positioned to engage substrate, potentially to
prevent diffusion. The channel of the Hsp104 hexamer collapses, further preventing substrate
diffusion, and makes a peristaltic pump motion with a wave of constriction moving N- Cterminally. Substrate can be engaged in NBD2 as channel collapse and NBD1 loop movements
pull substrate C-terminally. NBD1 exchanges ADP for ATP and the NTD and NBD1 reengage the
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substrate higher up. Once the hexamer has been engaged, iterative rounds of these actions
results in remodeled substrates.

4.2

Future directions
Our XF studies have identified a number of regions that may be involved in substrate

binding, Hsp70 interaction, hexamer cooperativity and signal transmission between domains. The
next steps would be to test these areas to confirm or identify their role, and to make mutations to
tailor Hsp104 to novel functions. In the NTD these regions include residues within the
hydrophobic patch, which we believe may bind substrate, as well as regions that may be involved
in Hsp70 interaction and an interface between the NTD, NBD1 and MD. Specifically, these
residues include A91, L92, V95, and L96 (for the hydrophobic patch), T87, Y90, K94, S124, and
S125 (for potential Hsp70 interaction site A) I102, Q103, K107 and S109 (for potential Hsp70
interaction site C) and residues that may be involved in the NTD:NBD1:MD interface, 8-15 (NTD),
39-52 (NTD), 148-166 (NTD-NBD1 linker), 230-240 (NBD1) and 496-498 (MD). Using
mutagenesis and biochemical assays (substrate binding, aggregate reactivation, etc.) we can test
whether these regions are involved in the activities we propose. The hydrophobic patch, if
confirmed to be involved in substrate binding, could be mutated to develop Hsp104 variants with
altered substrate specificities. Additionally, we have already identified potentiating mutations in
the proposed NTD:NBD1:MD interface (D498V [179], T499D and I230N [Amber Tariq, Shorter lab
unpublished data]), and therefore further mutations directed to these regions may reveal more
potentiated Hsp104 variants with altered behaviors. We would also like to be able to test whether
our proposed mechanism for the NBD1 291-GNGKD-295 loop, preventing substrate diffusion as
subunits rebind ATP, is correct. We would like to measure release of substrate due to ATP
hydrolysis after initial binding events, to confirm whether mutations in the loop result in more, or
faster release of substrate. To do this we would incubate Hsp104 variants with ATPγS and FITCcasein. Once the fluorescence polarization (FP) signal reaches equilibrium, we can add a large
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excess of ADP. As ATPγS is exchanged for ADP, some amount of substrate will be released. By
comparing the change in FP signal between WT Hsp104 and our loop variants, we will be able to
determine if the loop plays a role in preventing substrate diffusion.
Crosslinking studies and functional assays would further confirm the NBD2 hexameric
model. If the model is sound, it can be used as a template for creation of a full hexameric model,
with modifications to the original model based on the XF solvation data, particularly in the
placement of the coiled-coil MD. This starting model can be used to generate ensembles of
Hsp104 hexamers that can be filtered based on SAXS and XF constraints. These ensembles will
allow us to visualize different possible orientations of highly mobile domains such as the MD and
NTD.
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Chapter 5: Methods

5.1

Protein expression and purification
Hsp104 variants were generated using QuikChange lightning mutagenesis (Agilent).

Hsp104 variants were expressed and purified as N-terminally His6-tagged constructs in a
modified pPROEX HTb vector as described [233] or as untagged constructs in a pNOTAG vector
from the Lindquist lab. Briefly, expression of Hsp104 variants in BL21 RIL (His6-tagged
constructs) or BL21 DE3 RIL (untagged constructs) was induced with 1 mM IPTG overnight at
15°C once cells reached log phase. Cells were harvested via centrifugation (4,000 rpm, 4°C, 20
min), resuspended in lysis buffer – 40 mM HEPES-KOH pH 7.4, 500 mM KCl, 20 mM MgCl2,
2.5% (w/v) glycerol, 20 mM imidazole, 5 µM pepstatin A, complete protease inhibitor cocktail (1
EDTA-free tablet/50 mL), and 2 mM β-mercaptoethanol for His6-tagged constructs or 50 mM Tris,
pH 8, 10 mM MgCl2, 2.5% glycerol (w/v), 5 µM pepstatin A, complete protease inhibitor cocktail (1
EDTA-free tablet/50 mL) (Roche), 2 mM β-mercaptoethanol for untagged constructs. Cells were
lysed using a French press (Emulsiflex) homogenizer and cell debris removed via centrifugation
(16,000 rpm, 4°C, 20 min). A 50% slurry of lysis buffer equilibrated Ni-Sepharose beads (GE) (for
His6-tagged constructs, 2 mL beads per 1 L of cells) or Affi-Gel Blue Media resin (Bio-Rad) (for
untagged constructs, 3 mL resin per 1 L of cells) was added to the supernatant. Samples were
rotated at 20 rpm, 4°C for 3 hours (His6-tagged constructs) or 5 hours (untagged constructs).
After incubation the beads/resin were washed three time, with 1) wash buffer – 40 mM HEPESKOH pH 7.4, 140 mM KCl, 10 mM MgCl2, 2.5% (w/v) glycerol, 20 mM imidazole, 2 mM βmercaptoethanol), 2) wash buffer with 1 M KCl, and 3) wash buffer (His6-tagged constructs), or 4
times with 50 mM Tris, pH 8, 10 mM MgCl2, 100 mM KCl, 2.5% glycerol (w/v), 2 mM βmercaptoethanol (for untagged constructs). The beads/resin were collected after each wash by
centrifugation at 2,000 rpm for 2 min at 4°C (Eppendorf 5810R centrifuge) and the supernatant
discarded. After washing the protein was eluted with wash buffer with 350 mM imidazole (for His6-
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tagged constructs) or wash buffer with 1 M KCl (for untagged constructs). After elution His6tagged and untagged constructs were buffer exchanged into buffer Q (20 mM Tris-HCl pH 8, 0.5
mM EDTA, 5 mM MgCl2, 50 mM NaCl) and purified via anion exchange using a Resource Q
column (GE) and a gradient of buffer Q+ (20 mM Tris-HCl pH 8, 0.5 mM EDTA, 5 mM MgCl2, 1 M
NaCl) Hsp104 typically elutes off the column at ~34% buffer Q+ (~31 mS/cm). All His6-tagged
constructs contain a TEV protease cleavage site. Prior to use, the His6-tag was cleaved off with
proTEV protease (Promega) or AcTEV protease (Invitrogen) according to manufacturer’s
instructions. His6-tagged Sup35 was purified as described from BL21 (DE3) pLysS cells [20, 81].
ClpP was expressed and purified as a C-terminally His6-tagged construct as described [179].
RepA1-70-GFP and GroEL

TRAP

were purified as described [113]. Firefly luciferase was from Sigma.

Hsc70, Hdj2, Hsp72 and Hsp40 were from Enzo Life Sciences, FITC-casein was from Sigma, and
creatine kinase was from Roche. Unless otherwise stated Hsp104 concentrations refer to the
hexamer.

5.2

Sup35 fiber inhibition assay
Amyloid fiber assembly of full length Sup35 was tracked by monitoring the change in

fluorescence of the amyloid binding dye thioflavin T (excitation at 450 nm, emission 482 nm) on a
Tecan Infinite M1000 [20, 81]. The assembly reactions were carried out in buffer alone (40 mM
HEPES 7.4, 15 0mM KCl, 20 mM MgCl2, 10% w/v glycerol, 1 mM GTP, 1 mM DTT, 5.1 mM ATP
and an ATP regenerating system (1 mM creatine phosphate, 0.25 µM creatine kinase) or buffer
with an Hsp104 variant. Reaction endpoints were also visualized by negative stain electron
microscopy [20, 81].

5.3

Luciferase reactivation
Luciferase aggregation and reactivation were performed as described [132]. Briefly, firefly
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luciferase (50 µM) was incubated in LRB (25 mM HEPES-KOH pH 7.4, 150 mM KOAc, 10 mM
MgOAc, 10 mM DTT) with 8 M urea at 30°C for 30 min to form aggregates. After a rapid 100-fold
dilution in LRB, the aggregates were flash frozen and stored at -80°C until use. Reactivation
assays were carried out with Hsp104 (1 µM), Hsp70 (Hsc70 or Hsp72 at 1 µM), Hsp40 (Hdj2, 1
µM), 5.1mM ATP, and an ATP regenerating system (1mM creatine phosphate, 0.25 µM creatine
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kinase) for 90 min at 25°C. Alternatively, Hsp70, Hsp40 and 5.1 mM ATP were replaced with 5.1
mM nucleotide of different ratios of ATP:ATPγS. Luciferase activity was assessed using a
luciferase assay system from Promega. Luminescence was measured on a Tecan Infinite M1000
2

or Safire plate reader.

5.4

In vivo thermotolerance assay (Michelle Go, Shorter lab)
Yeast thermotolerance assays were performed as described [179]. Briefly, W303

Δhsp104 (MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1, hsp104:kanMX4)
yeast was transformed with a centromeric pHSE plasmid encoding an Hsp104 variant [106]. The
strains were grown in SD-ura media to an OD600 of 0.5, and incubated at 37°C for 30 min to
induce Hsp104 expression. Cells were then heat shocked for 0-20 min at 50°C, immediately
transferred to ice for 2 min, and then spotted on SD-ura plates in a 5–fold dilution series. After a
two-day incubation at 30°C, plates were imaged for analysis. Alternatively, the thermotolerance
products were plated on SD-ura plates, and after a 2-day incubation at 30°C colonies were
counted using an acolyte automated colony counter (Synbiosis). Immunoblotting was used to
confirm expressions levels of Hsp104 and disease proteins (when applicable).

5.5

Testing toxicity suppression of human disease proteins (Dr. Meredith Jackrel,

Shorter lab)
Full length or NTD deletion Hsp104 variants harboring known potentiating mutations were
transformed into yeast with pAG303GAL-TDP-43, pAG303GAL-FUS, or pAG303GAL-α-syn. The
strains were then spotted in 5-fold dilution series on glucose (off) or galactose (on) media to test
for toxicity suppression [179].
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5.6

ATPase assay
Hsp104 variants (0.25 µM monomer) were incubated for 5 min at 25°C with ATP (1 mM).

ATPase activity was assessed using a malachite green phosphate detection kit (Innova).

5.7

Fluorescence polarization
Fluorescent polarization experiments with Hsp104 variants and FITC-casein were

performed as described [179]. Briefly, Hsp104 variants in increasing concentrations (10 nM-4 µM)
were added to FITC-casein (6 nM), and ATPγS (2 mM) in LRB. After a 20 min incubation
fluorescent polarization of the FITC-casein was measured using a Tecan Infinite M1000 plate
reader. For binding in the presence of ADP, ATPγS was replaced with 2 mM ADP, FITC-casein
was 100 nM and Hsp104 concentrations varied from 0.5-15 µM.

5.8

Casein degradation
FITC-casein degradation assays were performed as described [179]. Briefly, FITC-casein

(100 nM-60 µM) was incubated with HAP variants (1 µM), ClpP (21 µM monomer), 5.1 mM ATP
and an ATP regenerating system. Degradation of FITC-casein was monitored by measuring
fluorescence of free FITC (excitation 490 nm, emission 520 nm) using a Tecan Infinite M1000 or
2

Safire plate reader.

5.9

RepA1-70-GFP unfolding
RepA1-70-GFP assays were performed as described [179]. Briefly, RepA1-70-GFP (0.7 µM)

was added to GroEL

TRAP

(1.5 µM), WT or ΔN Hsp104 (1 µM), either 2.6 mM ATP and 2.5 mM

ATPγS (1:1) or 3.43 mM ATP and 1.67 mM ATPγS (2:1), BSA (0.02 mg/mL), Triton (0.005%) and
an ATP regenerating system (1 mM creatine phosphate, 0.25 µM creatine kinase). The decrease
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in fluorescence (excitation at 395 nm, emission 510 nm) over time was monitored using a Tecan
Infinite M1000.

134	
  
	
  

5.10

Mutant subunit doping
Luciferase aggregation and reactivation were performed as described [132] (see above).

Reactivation assays were carried out with Hsp104 (1 µM), Hsp72 (1 µM), Hdj2 (1 µM), 5.1 mM
ATP, and an ATP regenerating system (1 mM creatine phosphate, 0.25 mM creatine kinase) for
90 min at 25°C. Prior to addition, WT (or ΔN) Hsp104 and mutant were mixed in the following
ratios: 6:0, 5:1, 4:2, 3:3, 2:4, 1:5, 0:6 and incubated for 30 min on ice. Luciferase activity was
assessed using a luciferase assay system from Promega. Luminescence was measured on a
Tecan Infinite M1000.

5.11

Glutaraldehyde crosslinking
Glutaraldehyde crosslinking experiments were carried out as described [139]. Briefly,

Hsp104 variants were diluted to 0.04 mg/mL in 40 mM Hepes-KOH pH 7.4, 140 mM KCl, 10 mM
MgCl2, 1 mM DTT plus either 20 mM EDTA or 5 mM ATP. The samples were incubated with
glutaraldehyde (0.1%) for 12 min. The crosslinking reaction was quenched by addition of 1 M
glycine pH 6, and the proteins were precipitated using trichloroacetic acid. After two washes with
chilled acetone the samples were run on an SDS-PAGE gel and reactions products visualized
using a silver stain kit (Invitrogen).

5.12

Synchrotron hydroxyl radical footprinting (XF)

5.12.1 Sample irradiation
WT Hsp104 was purified as in [233], with a final step of gel filtration using a Superdex
200 column (GE) equilibrated in 50 mM Cacodylate pH 7.0, 140 mM KCl, 10 mM MgCl2, (for the
hexamer) or 50 mM Cacodylate pH 7.0, 500 mM KCl, and 20 mM MgCl2 (for the monomer, as
confirmed by Size Exclusion Chromatography followed by Multi Angle Light Scattering, SECMALS (Wyatt)). Samples were kept on ice and transported to Brookhaven National Laboratory
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(Upton, NY). All samples were kept on ice and diluted at the beamline 10 min prior to use to 10
µM Hsp104 in 50 mM Cacodylate pH 7.0, 140 mM KCl, 10 mM MgCl2, and 1 mM ADP or ATPγS
(for the hexamer) or 50 mM Cacodylate pH 7.0, 500 mM KCl, and 20 mM MgCl2 (for the
monomer). X-ray dose- dependent oxidation of Alexa488 (Invitrogen) in the three buffer
conditions was used to determine optimal exposure times and provide normalization constants.
The samples were exposed to a mirror-focused synchrotron x-ray beam (5.5 mrad angle, focus
value of 6 mm) at the X28C beamline of the National Synchrotron Light Source at Brookhaven
National Laboratory for 0-20 ms. The exposure time of the samples was controlled by flow rate
through the flow cell of a KinTek (Austin, TX) stopped flow apparatus [218]. Oxidation was
immediately quenched by the addition of 10 mM methioninamide, and samples were frozen with
dry ice, transported to the University of Pennsylvania and stored at -80°C.

5.12.2 Mass spectrometry on the XF samples
The irradiated samples were thawed on ice and diluted to 1 µM in 5mM HEPES NaOH
pH 7.0, 140 mM KCl, 10 mM MgCl2, 1 mM DTT, 1% TFA and immediately injected onto an in-line
fragmentation-separation/MS analysis system. Samples first passed through an immobilized
pepsin column onto a C8 trap column and washed for 3 min (2% acetonitrile, 1% formic acid, pH
2, 0°C). Samples then flowed onto an analytical C18 column, were eluted using a gradient
optimized for the highly charged Hsp104 peptides (6 µL/min non-linear 2-50% acetonitrile
gradient, 0.1% formic acid, pH 2 and 0°C), and injected by electron spray ionization into an LTQ
Orbitrap XL mass spectrometer (Thermo Scientific). The four most abundant peptides from each
scan was selected for fragmentation by CID and measured in the LTQ stage.
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5.12.3 Identification of oxidatively modified peptides using ExMS-CL (Dr. Zhong-yuan
Kan, Englander lab)
A modified version of the ExMS program, called ExMS-CL (which stands for “covalent
labeling”), was used to process/analyze the x-ray footprinting MS/MS data to identifying oxidative
modifications on the protein samples. Its workflow can be briefly described as follows. First,
ExMS-CL makes a peptide list of the target protein including unmodified and modified peptides.
The unmodified peptides are obtained from searching MS/MS runs (similar to SEQUEST), with a
user-set score threshold (in this case a p score cut-off of 0.01) to build a “peptide pool”. Based on
the sequence of the unmodified “peptide pool” and the table of amino acid specific potential
oxidative modifications (see Table 1 in ref [213]), ExMS-CL enumerates a full list of peptides with
all potential modifications. For each peptide in the list, its theoretical monoisotopic m/z and
isotopic peak intensity distribution (the envelope shape) are calculated. The reference retention
time (RT) of unmodified peptides is directly copied from the MS/MS search result, and ExMS-CL
uses a user-set shift (e.g., -3 minutes to +5 minutes) to create and use a specific RT search
window for modified version of peptides. All of this information is saved together in the peptide
list.
By using the above compiled list, ExMS-CL searches each peptide in the MS1 data,
within each specific RT window for modified versions of peptides (see Figure 4 for an example of
unmodified and modified versions of a peptide identified by ExMS-CL). ExMS-CL matches
peptide theoretical masses and envelope shapes to the experimental data, and performs multiple
tests and checks as in the original ExMS (algorithm details described in ref [220]) to ensure the
identification is correct. At the end of this step, normal ExMS outputs are saved, including every
identified peptides RT range, summed isotopic peak mass spectrum and centroid. Next, ExMSCL confirms the modified peptides and locates the modification sites at MS1 and MS2 levels.
From the MS1 ExMS output, peptide (“goodModPepSet”) and protein sequence (“proModTable”)
tables are compiled to list all the modifications found with their individual position on the peptide,
the peptide intensity quantification, and the number of modification possibilities (“sharing times”).
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The latter information can be used to judge if the modification can be uniquely assigned to an
amino acid location. Further, ExMS-CL looks into the MS2 data by matching the parent ions to
the mass of found modified peptides, then extracting the matched experimental CID spectra and
comparing with the peptide’s predicted CID spectra. A MS2 score is calculated to help confirm the
identity of that modified peptide. Finally, ExMS-CL reports the analysis results of identified
peptides in both modified and unmodified forms.

5.12.4 Analysis of modification rate of identified peptides using Matlab (Dr. Matthew
Sochor, Lewis lab)
Output of ExMS-CL was read into Matlab (Mathworks) and analyzed using custom
scripts. Modified and unmodified versions of peptides and their intensities were read from the
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ExMS-CL output files and matched up. Fraction unmodified was calculated for each MS/MS
sample using the peptide intensities (the sum of unmodified versions of the peptide divided by the
sum of all modified and unmodified versions of the peptide). For each timepoint, the MS/MS run
outputs were averaged together and standard deviation calculated. For each peptide, the average
fraction unmodified was reported for each timepoint. Once time-dependent modification was
calculated, each peptide was binned into one of three categories by the Matlab program, no timedependent modification (0-1 timepoints after time 0 were modified with respect to time 0),
sporadic modification (2 timepoints after time 0 were modified with respect to time 0), and timedependent modification (greater than 2 timepoints after time 0 were modified with respect to time
0). For the peptides that displayed time-dependent modification, the program used the first four
timepoints (0, 2.5, 5, and 7.5 ms) to determine the rate of modification by fitting to a first order
exponential decay. The earliest timepoints were used due to evidence of over-oxidation in many
of the 10 and 20 ms timepoints. Each of the fits was visually checked and manually refitting using
Origin 8.1 was used when the Matlab program failed to converge onto a visually accurate fit to the
data.

5.13

Small and wide angle x-ray scattering (SAXS/WAXS)

5.13.1 SAXS methods overview
X-ray scattering data were collected at beamline 4-2 at the Stanford Synchrotron
Radiation Laboratory (SSRL, Menlo Park, CA), and beamline X9 at the National Synchrotron
Light Source (NSLS, Upton, NY) (details specific to each beamline below). Data were collected at
multiple concentrations between 1.5 mg/mL and 6.0 mg/mL. The two-dimensional scattering
images were collected on CCD detectors, and circularly averaged using software developed at
the individual beamlines to yield one-dimensional scattering profiles as a function of momentum
transfer q (q=4πsin(θ)/λ, where 2π is the scattering angle and λ is the wavelength. The raw
scattering data were scaled and buffer subtracted using the program PRIMUS [234]. Each
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individual scattering curve was visually inspected for radiation damage and aggregation prior to
averaging, including Guinier and Kratky plot analysis. For data collected at NSLS, where both
SAXS and WAXS data are collected on separate detectors simultaneously, averaged scattering
curves from the SAXS and WAXS detectors were scaled and merged in PRIMUS to yield a lownoise composite curve. The radii of gyration (Rg) were initially calculated using Guinier plots
[235]. Distance distribution functions P(r) were calculated by the program GNOM [236] using an
indirect Fourier transform. The maximum dimension of the particle (Dmax) was determined by
examining the quality of fit to the experimental data for a Dmax range of 180 Å to 280 Å, varied in 5
Å. Fits were assessed by maximizing the Total Estimate figure, minimizing the discrepancy
between calculated and experimental profiles, and optimizing the visual properties of the shape
distribution function. Values for Rg were computed from the second moment of the P(r) and
compared favorably to those calculated using Guinier plot analysis. The Porod volume and P
value were calculated by the java-based program ScÅtter: http://www.bioisis.net/tutorial/9. The
mass of the particle was calculated from Qr as described [237].

5.13.2 Small-Angle X-ray Scattering at SSRL Beamline 4-2
SAXS data were collected at beamline 4-2 at the Stanford Synchrotron Radiation
Laboratory (SSRL, Menlo Park, CA) at room temperature with a sample to detector distance of
1600 mm. Using software developed at the beamline, two-dimensional scattering profiles
collected using a Rayonix MX225-HE detector were converted into one-dimensional intensity
-1

profiles. The x-ray wavelength was 1.2 Å and the angular range was 0.0140 ≤ q ≥ 0.4435 Å . The
protein samples and matching buffer solutions, 30 µL for each measurement, were exposed for
ten 10 s exposures in a 1.2 mm path capillary with thin mica windows sealed across the
evacuated flight path. Each exposure was checked for radiation damage by the automated
software prior to averaging. After each measurement the capillary was washed thoroughly and
purged with compressed nitrogen.
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5.13.3 Small and Wide-Angle X-ray Scattering at NSLS Beamline X9
SAXS and WAXS data were collected simultaneously at beamline X9 at the National
Synchrotron Light Source (NSLS, Upton, NY) at 10°C, or 25°C for the ADP-AlFx state, by two
overlapping detectors, a Mar 165 CCD SAXS detector 3.4 m from the sample, and a custom built
Photonic Science CCD WAXS detector. The two-dimensional images were converted into onedimensional scattering profiles using software developed at the beamline. The x-ray wavelength
was 0.855 Å and the angular range collected was 0.00550 ≤ q ≥ 1.0060; an angular range of
0.0100 ≤ q ≥ 0.7950 was used for data analysis and reconstructions; reconstructions were also
carried out with q=0.4950, which compared favorably to the reconstructions to q=0.7950. The
sample cell contained a glass capillary sealed across the evacuated chamber. The protein
samples and matching buffer solutions were flowed through the capillary and oscillated during
exposure to reduce radiation damage. For data collection 30 µL of the protein sample or
matching buffer solution was exposed for 180 s, subdivided into 3 60 s exposures of 10 µL.

5.13.4 Shape reconstructions from SAXS/WAXS data
Shape reconstructions of the hexamer were generated using the program GASBOR
[201]. Information required for GASBOR modeling is the x-ray scattering profile, the number of
residues to be modeled (GASBOR assigns a dummy reside to represent each residue), and the
Dmax. Six-fold symmetry was imposed. Since each inverse scattering has no one unique solution,
ten independent ab initio reconstructions were performed for each state. Regions that are flexible
are assigned different positions in individual simulations. The ten independent dummy residue
reconstructions were aligned and scored based on the normalized spatial discrepancy (NSD)
[238]. The individual reconstructions were only included if their NSD < mean NSD + 2 * variation.
The included reconstructions were averaged and filtered to yield a final most-probable model
using the DAMAVER suite of programs [202]. The individual bead models were visualized in
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PyMOL (DeLano, W.L. The PyMOL Molecular Graphics System (2002) on World Wide Web
http://www.pymol.org). The filtered and unfiltered average models were converted to volume
envelopes using SITUS [239] and visualized using Chimera [240].

5.13.5 Channel calculations (Dr. Matthew Sochor, Lewis lab)
5.13.5.1

Volume measurement

The situs maps were converted to mrc maps using map2map, part of the SITUS suite of
programs [239]. The three-dimensional electron density file in the .mrc format was imported into
Matlab (Mathworks) using a custom script which parses the file into a three dimensional matrix of
electron density. The read function also extracts the voxel dimensions in order to scale the
measurement. The built in Matlab function “edge” was used to find the edges of two-dimensional
slices of the electron density using the Sobel method. The Sobel method finds the edges by
approximating the first derivative over the image; maxima of the first derivative are edges.
A custom script was then used to find edges for each two-dimensional slice of the density
matrix. The x, y, and z coordinates of each edge point were stored in an array and the array
scaled by the voxel dimensions. This array is a list of all three-dimensional vectors; each vector
points to a unique edge point. The built in Matlab function “convhulln” was then used to convert
this vector array into a convex hull and it measured the volume of the hull. The convex hull is the
shell of the channel and the volume is the volume of the Hsp104 hexamer channel.

5.13.5.2

Distance measurement

Distance was measured for each slice of the channel. First, edges were found for each
slice using the Matlab function “edge”. A horizontal mid-line of the channel was extracted and the
distance from edge to edge was measured, scaled by the horizontal voxel dimension. The vertical
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mid-line of the channel was then extracted and the edge-to-edge scaled distance was measured.
Both distances were stored in an array. Then the slice was rotated 5 degrees and the algorithm
was repeated to measure horizontal and vertical edge-to-edge, scaled distances. When the
image had been rotated 45 degrees, every distance across the channel had been measured for a
total of 18 distance measurements. The algorithm was then iterated over every slice of the
density to measure the channel widths for each slice. The final array of distances was then output
for further processing.

5.14

Hydrogen – deuterium exchange (Alec Ricciuti, Englander lab)
Hydrogen-deuterium exchange was carried out as described [220, 241] on the monomer,

apo hexamer, hexamer with ADP and hexamer with ATPγS at several deuterium exchange
timepoints. Curves showing deuterium incorporation versus time for peptides from different
samples allowed for the determination of protection factors for the hexameric states when
compared to the monomer.

5.15

Homology modeling
Hsp104 was homology modeled domain by domain using SWISS-MODEL [242-244]

based on the ClpB crystal structures 1khy (N terminal domain) [142] and 1qvr (NBD1, MD, NBD2)
[102]. Hydrogen-exchange (HD) experiments have revealed that the Hsp104 monomer homology
modeled off the tClpB structure has accurately placed loops and stable secondary structure (data
not shown, Alec Ricciuti and Walter Englander, manuscript in preparation), suggesting that the
homology model is reasonably accurate. The separate domains were then rigid body fit into the
volume envelope for the hexamer with ATP generated by the SAXS analysis using Chimera
[240].
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